Blueprint

0001654954-19-009579.txt : 20190814 0001654954-19-009579.hdr.sgml : 20190814 20190814161630 ACCESSION NUMBER: 0001654954-19-009579 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20190630 FILED AS OF DATE: 20190814 DATE AS OF CHANGE: 20190814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 191026597 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 10-Q 1 cvm_10q.htm QUARTERLY REPORT Blueprint

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2019

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF

THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______________ to ______________.

Commission File Number 001-11889

CEL-SCI CORPORATION

Colorado		84-0916344
State or other jurisdiction incorporation		(IRS) Employer Identification Number

8229 Boone Boulevard, Suite 802

Vienna, Virginia 22182

Address of principal executive offices

(703) 506-9460

Registrant's telephone number, including area code

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports) and (2) had been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check One):

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Class of Stock	No. Shares Outstanding	Date
Common	34,805,299	August 13, 2019

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CVM	NYSE American

TABLE OF CONTENTS

PART I FINANCIAL INFORMATION

Item 1.		Page

	Condensed Balance Sheets at June 30, 2019 and September 30, 2018 (unaudited)	3

	Condensed Statements of Operations for the nine months ended June 30, 2019 and 2018 (unaudited)	4

	Condensed Statements of Operations for the three months ended June 30, 2019 and 2018 (unaudited)	5

	Condensed Statements of Cash Flows for the nine months ended June 30, 2019 and 2018 (unaudited)	6

	Notes to Condensed Financial Statements (unaudited)	8

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures about Market Risks	24

Item 4.	Controls and Procedures	24

PART II

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	25

Item 6.	Exhibits	25

	Signatures	26

CEL-SCI CORPORATION

CONDENSED BALANCE SHEETS

(UNAUDITED)

	JUNE 30,	SEPTEMBER 30,
ASSETS	2019	2018

Current Assets:
Cash and cash equivalents	$9,485,495	$10,310,044
Receivables	118,264	118,657
Prepaid expenses	233,784	364,622
Inventory used for R&D and manufacturing	754,825	645,238

Total current assets	10,592,368	11,438,561

Plant, property and equipment, net	15,948,864	16,218,851
Patent costs, net	272,488	258,093
Deposits	1,670,917	1,670,917

Total Assets	$28,484,637	$29,586,422



LIABILITIES AND STOCKHOLDERS' EQUITY

Current Liabilities:
Accounts payable	$2,078,800	$5,743,913
Accrued expenses	122,030	205,310
Due to employees	761,027	764,941
Derivative instruments, current portion	1,249,835	2,498,606
Other current liabilities	16,009	14,029

Total current liabilities	4,227,701	9,226,799

Derivative instruments, net of current portion	9,482,995	6,818,458
Lease liability	13,475,704	13,379,962
Deferred income	126,849	126,795
Other liabilities	25,084	33,492

Total liabilities	27,338,333	29,585,506

Commitments and Contingencies

STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value-200,000 shares authorized;
-0- shares issued and outstanding	-	-
Common stock, $.01 par value - 600,000,000 shares authorized;
34,066,914 and 28,034,487 shares issued and outstanding
at June 30, 2019 and September 30, 2018, respectively	340,669	280,346
Additional paid-in capital	349,683,796	331,312,184
Accumulated deficit	(348,878,161)	(331,591,614)

Total stockholders' equity	1,146,304	916

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$28,484,637	$29,586,422

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

NINE MONTHS ENDED JUNE 30, 2019 and 2018

(UNAUDITED)

	2019	2018

Grant income	$386,121	$297,045

Operating Expenses:
Research and development	7,956,203	7,713,873
General and administrative	6,981,079	5,823,694

Total operating expenses	14,937,282	13,537,567

Operating loss	(14,551,161)	(13,240,522)

Other income	54,575	52,984

(Loss) gain on derivative instruments	(3,316,384)	187,967

Other non-operating gain (loss)	1,877,197	(171,468)

Interest expense, net	(1,350,774)	(3,739,494)

Net loss available to common shareholders	$(17,286,547)	$(16,910,533)


Net loss per common share
Basic and Diluted	$(0.58)	$(1.17)

Weighted average common shares outstanding
Basic and Diluted	30,046,241	14,486,351

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

THREE MONTHS ENDED JUNE 30, 2019 and 2018

(UNAUDITED)

	2019	2018

Grant income	$108,938	$86,459

Operating Expenses:
Research and development	2,298,555	2,425,562
General and administrative	3,020,482	1,748,971

Total operating expenses	5,319,037	4,174,533

Operating loss	(5,210,099)	(4,088,074)

Other income	18,448	17,711

Loss on derivative instruments	(7,905,519)	(8,618)

Other non-operating gain (loss)	1,455,844	(149,359)

Interest expense, net	(443,442)	(1,786,228)

Net loss available to common shareholders	$(12,084,768)	$(6,014,568)


Net loss per common share
Basic and Diluted	$(0.37)	$(0.36)

Weighted average common shares outstanding
Basic and Diluted	33,051,888	16,651,297

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

NINE MONTHS ENDED JUNE 30, 2019 and 2018

(UNAUDITED)

	2019	2018

Net loss	$(17,286,547)	$(16,910,533)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization	513,028	485,710
Share-based payments for services	688,070	349,319
Share-based payments for interest	-	80,716
Equity based compensation	2,626,311	2,193,402
Common stock contributed to 401(k) plan	108,485	109,073
Shares issued for settlement of clinical research costs	1,290,000	2,957,400
Loss on prepaid research and development	-	471,157
Loss (gain) on derivative instruments	3,316,384	(187,967)
Amortization of debt discount	-	1,956,424
Inducement expense	-	291,234
Capitalized lease interest	95,742	125,044
(Increase)/decrease in assets:
Receivables	393	98,829
Prepaid expenses	11,047	122,627
Inventory used for R&D and manufacturing	(109,587)	44,364
Deposits	-	150,000
Increase/(decrease) in liabilities:
Accounts payable	(3,567,182)	(1,960,438)
Accrued expenses	(113,280)	(74,856)
Due to employees	(3,914)	548,982
Other liabilities	(2,544)	4,819

Net cash used in operating activities	(12,433,594)	(9,144,694)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(171,321)	(1,015)
Expenditures for patent costs	(115,476)	(2,437)

Net cash used in investing activities	(286,797)	(3,452)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	-	7,091,536
Payments of stock issuance costs	(90,224)	(94,773)
Proceeds from exercise of warrants	11,657,590	2,133,677
Proceeds from exercise of options	97,290	-
Proceeds from the purchase of stock by officers and directors	234,997	-
Payments on obligations under capital lease	(3,811)	(5,082)

Net cash provided by financing activities	11,895,842	9,125,358

NET DECREASE IN CASH AND CASH EQUIVALENTS	(824,549)	(22,788)

CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,310,044	2,369,438

CASH AND CASH EQUIVALENTS, END OF PERIOD	$9,485,495	$2,346,650

See notes to condensed financial statements.

CEL-SCI CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

NINE MONTHS ENDED JUNE 30, 2019 and 2018

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

	2019	2018
Capitalizable patent costs included in current liabilities	$30,000	$61,501
Capital lease obligation included in accounts payable	$434	$408
Exercise of derivative liabilities	$1,900,618	$784,119
Stock issuance costs included in current liabilities	$8,010	$-
Prepaid consulting services paid with issuance of common stock	$(119,791)	$113,786
Notes payable converted into common shares	$-	$2,294,300



Cash paid for interest expense	$1,355,676	$1,312,664

See notes to condensed financial statements.

CEL-SCI CORPORATION

NOTES TO CONDENSED FINANCIAL STATEMENTS

THREE MONTHS ENDED JUNE 30, 2019 AND 2018 (UNAUDITED)

BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2018.

In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2019 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2018 is derived from the September 30, 2018 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements. The results of operations for the nine and three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire year.

The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations, which are expected for the foreseeable future, and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements – The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2019 and September 30, 2018.

On December 22, 2017, the “Tax Cuts and Jobs Act” (the “Tax Act"), was signed into law by the President of the United States (U.S.). The Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks. The Company has accounted for the income tax effects of the Act in applying FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred income tax asset, there was no impact to the amounts reported in the Company’s financial statements resulting from the Tax Act.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense. For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.

Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's balance sheet.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as an expense over the requisite service or vesting period.

Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.

The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.

The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.

Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

New Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), (“ASU 2018-7”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, non-employee share-based payments would be measured at the grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure awards that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company’s financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (except of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. As permitted by the guidance, the Company has an option to retain the original lease classification and historical accounting for initial direct costs for leases existing prior to the adoption date. Furthermore, the Company will not have to reassess contracts entered into prior to the adoption date for the existence of a lease. The Company also has an option not to restate prior periods for the impact of the adoption of the new standard and may instead recognize a cumulative-effect adjustment to beginning retained earnings as of October 1, 2019 for any prior period income statement effects identified. The Company is evaluating the effect that adoption of this new standard will have on the Company’s financial statements and related disclosures.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

OPERATIONS AND FINANCING

The Company has incurred significant costs since its inception for the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials. The Company has funded such costs with proceeds from loans and the public and private sale of its common stock. The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company is taking cost-cutting initiatives, as well as exploring other sources of funding, to finance operations over the next 12 months. The Company believes that there is a high likelihood that it will continue to receive funds from warrant exercises similar to the way it has received funds during the past 12 months. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

The Company is currently in the final stages of its large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt issuances and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all. If the Company does not raise the necessary amounts of money, it may have to curtail its operations until it can raise the required funding.

The financial statements have been prepared assuming the Company will continue as a going concern, but due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $54.7 million as of June 30, 2019 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $5.6 million for the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by the rate of death accumulation in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.

Nine hundred twenty-eight (928) head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study end point is a 10% increase in overall survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment regimen. The determination if the study end point has been met will occur when there are a total of 298 deaths in those two groups.

STOCKHOLDERS’ EQUITY

The changes in stockholders’ equity during the nine months ended June 30, 2019 are as follows:

			Additional
	Common	Stock	Paid-In	Accumulated
	Shares	Amount	Capital	Deficit	Total

BALANCES AT OCTOBER 1, 2018	28,034,487	$280,346	$331,312,184	$(331,591,614)	$916
Warrant exercises	298,682	2,987	646,766	-	649,753
401(k) contributions paid in common stock	12,279	123	35,118	-	35,241

Stock issued to nonemployees for services	62,784	628	201,752	-	202,380
Shares returned for settlement of clinical research costs	(564,905)	(5,649)	5,649	-	-
Equity based compensation - employees	-	-	573,660	-	573,660
Net income	-	-	-	1,245,902	1,245,902

BALANCES AT DECEMBER 31, 2018	27,843,327	278,435	332,775,129	(330,345,712)	2,707,852

Warrant exercises	1,523,933	15,239	2,640,395	-	2,655,634
401(k) contributions paid in common stock	10,419	104	36,779	-	36,883
Stock issued to nonemployees for services	77,449	774	224,855	-	225,629
Equity based compensation - employees	(3,500)	(35)	530,865	-	530,830
Shares issued for settlement of clinical research costs	500,000	5,000	1,285,000	-	1,290,000
Stock issuance costs	-	-	(43,625)	-	(43,625)
Net loss	-	-	-	(6,447,681)	(6,447,681)

BALANCES AT MARCH 31, 2019	29,951,628	299,517	337,449,398	(336,793,393)	955,522

Warrant exercises	4,014,109	40,141	10,212,680	-	10,252,821
401(k) contributions paid in common stock	4,339	43	36,318	-	36,361
Stock issued to nonemployees for services	20,825	208	140,062	-	140,270
Equity based compensation - employees	(4,000)	(40)	1,521,861	-	1,521,821
Option exercises	42,770	428	96,862	-	97,290
Purchase of stock by officers and directors	37,243	372	234,625	-	234,997
Stock issuance costs	-	-	(8,010)	-	(8,010)
Net loss	-	-	-	(12,084,768)	(12,084,768)
BALANCES AT JUNE 30, 2019	34,066,914	$340,669	$349,683,796	$(348,878,161)	$1,146,304

The changes in stockholders’ deficit during the nine months ended June 30, 2018 are as follows:

			Additional
	Common	Stock	Paid-In	Accumulated
	Shares	Amount	Capital	Deficit	Total

BALANCES AT OCTOBER 1, 2017	11,903,133	$119,031	$296,298,401	$(299,754,409)	$(3,336,977)

Sale of common stock	1,289,478	12,895	2,437,105	-	2,450,000
401(k) contributions paid in common stock	18,984	190	35,690	-	35,880
Stock issued to nonemployees for services	13,705	137	25,270	-	25,407
Equity based compensation - employees	-	-	1,448,098	-	1,448,098
Warrants issued with notes payable	-	-	656,382	-	656,382
Conversion of notes payable to common stock	32,751	328	74,672	-	75,000
Net loss	-	-	-	(6,187,830)	(6,187,830)
BALANCES AT DECEMBER 31, 2017	13,258,051	132,581	300,975,618	(305,942,239)	(4,834,040)

Sale of common stock	2,501,145	25,011	4,652,130	-	4,677,141
401(k) contributions paid in common stock	25,901	259	36,261	-	36,520
Stock issued to nonemployees for services	124,082	1,241	227,254	-	228,495
Equity based compensation - employees	-	-	279,817	-	279,817
Conversion of notes payable to common stock	55,373	554	108,746	-	109,300
Shares issued for settlement of clinical research costs	660,000	6,600	1,240,800	-	1,247,400
Stock issuance cost	-	-	(94,773)	-	(94,773)
Net loss	-	-	-	(4,708,135)	(4,708,135)
BALANCES AT MARCH 31, 2018	16,624,552	166,246	307,425,853	(310,650,374)	(3,058,275)

Warrant exercises	1,117,644	11,177	2,906,619	-	2,917,796
401(k) contributions paid in common stock	39,862	399	36,274	-	36,673
Stock issued to nonemployees for services	81,604	816	208,387	-	209,203
Equity based compensation - employees	-	-	465,487	-	465,487
Conversion of notes payable and interest to common stock	1,106,806	11,068	2,179,648	-	2,190,716
Shares issued for settlement of clinical research costs	600,000	6,000	1,704,000	-	1,710,000
Warrants issued with notes payable	-	-	291,234	-	291,234
Net loss	-	-	-	(6,014,568)	(6,014,568)
BALANCES AT JUNE 30, 2018	19,570,468	$195,706	$315,217,502	$(316,664,942)	$(1,251,734)

Underlying share information for equity compensation plans as of June 30, 2019 is as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Options Plans	138,400	99,962	N/A	385
Non-Qualified Stock Option Plans	6,387,200	6,193,237	N/A	115,156
Stock Bonus Plans	783,760	N/A	327,267	456,460
Stock Compensation Plan	634,000	N/A	122,221	493,369
Incentive Stock Bonus Plan	640,000	N/A	616,500	23,500

Underlying share information for equity compensation plans as of September 30, 2018 is as follows:

Name of Plan	Total Shares Reserved Under Plans	Shares Reserved for Outstanding Options	Shares Issued	Remaining Options/Shares Under Plans

Incentive Stock Option Plans	138,400	123,558	N/A	385
Non-Qualified Stock Option Plans	3,387,200	3,036,569	N/A	309,526
Stock Bonus Plans	783,760	N/A	297,230	486,497
Stock Compensation Plan	134,000	N/A	118,590	15,410
Incentive Stock Bonus Plan	640,000	N/A	624,000	16,000

Stock option activity:

	Nine Months Ended June 30,
	2019	2018
Granted	3,268,862	1,858,108
Exercised	42,770	-
Expired	29,322	26,395
Forfeited	63,698	1,393

	Three Months Ended June 30,
	2019	2018
Granted	3,268,362	1,847,808
Exercised	42,770	-
Expired	26,922	2,016
Forfeited	39,505	-

During the quarter ended June 30, 2019, the Company adopted the 2019 Stock Compensation Plan, which authorized the issuance of up to 500,000 shares of common stock to officers, directors, employees and consultants.

Employee stock based compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts. Stock based compensation expense is included in general and administrative expenses on the statements of operations.

Non-employee stock based compensation expense includes the value of shares and options issued under consulting arrangements. At June 30, 2019 and September 30, 2018, approximately $88,000 and $207,000, respectively, are included in prepaid expenses.

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at June 30, 2019:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants	Exercise Price	Expiration Date
Series N	8/18/2008	85,339	$3.00	2/18/2020
Series V	5/28/2015	810,127	$19.75	5/28/2020
Series UU	6/11/2018	163,544	$2.80	6/11/2020
Series W	10/28/2015	688,930	$16.75	10/28/2020
Series X	1/13/2016	120,000	$9.25	1/13/2021
Series Y	2/15/2016	26,000	$12.00	2/15/2021
Series ZZ	5/23/2016	20,000	$13.75	5/18/2021
Series BB	8/26/2016	16,000	$13.75	8/22/2021
Series Z	5/23/2016	264,000	$13.75	11/23/2021
Series FF	12/8/2016	68,048	$3.91	12/1/2021
Series CC	12/8/2016	611,463	$5.00	12/8/2021
Series HH	2/23/2017	6,500	$3.13	2/16/2022
Series AA	8/26/2016	200,000	$13.75	2/22/2022
Series JJ	3/14/2017	9,450	$3.13	3/8/2022
Series LL	4/30/2017	26,398	$3.59	4/30/2022
Series MM	6/22/2017	893,491	$1.86	6/22/2022
Series NN	7/24/2017	473,798	$2.52	7/24/2022
Series OO	7/31/2017	60,000	$2.52	7/31/2022
Series II	3/14/2017	95,000	$3.00	9/14/2022
Series RR	10/30/2017	495,326	$1.65	10/30/2022
Series SS	12/19/2017	514,476	$2.09	12/18/2022
Series TT	2/5/2018	760,758	$2.24	2/5/2023
Series PP	8/28/2017	112,500	$2.30	2/28/2023
Series WW	7/2/2018	1,950	$1.63	6/28/2023
Series VV	7/2/2018	90,000	$1.75	1/2/2024
Consultants	7/28/17	10,000	$2.18	7/27/2027

Derivative Liabilities

The table below presents the fair value of the warrant liabilities at the balance sheet dates:

	June 30, 2019	September 30, 2018
Series S warrants	$-	$33
Series V warrants	1,249,835	770,436
Series W warrants	2,131,237	999,081
Series Z warrants	1,172,626	487,767
Series ZZ warrants	72,185	34,215
Series AA warrants	963,990	380,474
Series BB warrants	64,256	28,456
Series CC warrants	3,699,989	1,779,724
Series DD warrants	-	1,249,287
Series EE warrants	-	1,249,287
Series FF warrants	433,091	188,921
Series GG warrants	-	607,228
Series HH warrants	44,050	58,816
Series II warrants	660,020	660,135
Series JJ warrants	64,252	88,642
Series KK warrants	-	656,930
Series LL warrants	177,299	77,632
Total warrant liabilities	$10,732,830	$9,317,064

The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:

	2019	2018
Series S warrants	$33	$(756,261)
Series V warrants	(479,399)	22,842
Series W warrants	(1,132,156)	18,478
Series Z warrants	(684,859)	34,682
Series ZZ warrants	(37,970)	2,103
Series AA warrants	(583,516)	28,337
Series BB warrants	(35,800)	1,988
Series CC warrants	(2,007,287)	181,244
Series DD warrants	1,249,287	5,492
Series EE warrants	1,249,287	5,492
Series FF warrants	(244,170)	23,119
Series GG warrants	195,228	170,131
Series HH warrants	(22,859)	7,962
Series II warrants	(593,960)	250,578
Series JJ warrants	(32,954)	11,970
Series KK warrants	(55,622)	169,808
Series LL warrants	(99,667)	10,002
Net (loss) gain on warrant liabilities	$(3,316,384)	$187,967

The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:

	2019	2018
Series S warrants	$-	$(768,188)
Series V warrants	(974,251)	26,389
Series W warrants	(1,748,184)	42,609
Series Z warrants	(799,690)	26,587
Series ZZ warrants	(50,608)	1,914
Series AA warrants	(676,784)	19,661
Series BB warrants	(43,536)	1,695
Series CC warrants	(2,346,985)	139,325
Series DD warrants	-	36
Series EE warrants	-	36
Series FF warrants	(278,773)	15,818
Series GG warrants	88,478	132,712
Series HH warrants	(33,501)	5,279
Series II warrants	(709,303)	199,970
Series JJ warrants	(48,880)	7,960
Series KK warrants	(169,089)	132,884
Series LL warrants	(114,413)	6,695
Net loss on warrant liabilities	$(7,905,519)	$(8,618)

The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.

In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.

Expiration of Derivative Liabilities

On December 10, 2018, 1,360,960 Series DD and 1,360,960 Series EE warrants, with an exercise price of $4.50, expired. The expiration dates of these warrants had been previously extended and such modifications were reflected in the fair value measurements of the warrants on the dates of modification.

On October 11, 2018, 327,729 Series S warrants, with an exercise price of $31.25, expired. The exercise price of these warrants had been previously repriced under temporarily revised terms. During the quarter ended June 30, 2018 and under the revised terms, 709,391 previously outstanding warrants were exercised for total proceeds of approximately $1.2 million,

Securities Purchase Agreements

The Company has entered into several Securities Purchase Agreements (SPAs) with Ergomed plc, one of its Clinical Research Organizations responsible for managing the Phase 3 clinical trial, to facilitate a partial payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock as a forbearance fee in exchange for Ergomed’s agreement to provisionally forbear collection of the payables in an amount equal to the net proceeds from the sales of the shares issued to Ergomed. Upon issuance, the Company expenses the full value of the shares as Other Non-Operating Gain/Loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed. Any amounts received from the sale of the shares in excess of the payables will be applied towards the satisfaction of any future amounts owed.

On December 31, 2018, the prior SPA expired. Pursuant to that arrangement, Ergomed returned 564,905 unsold shares for cancellation. The par value of those shares was reclassed from Common Stock to Additional Paid-In Capital on the balance sheet.

On January 9, 2019, the Company entered into a new SPA under which it issued Ergomed 500,000 restricted shares of the Company’s common stock valued at approximately $1.3 million. This current SPA expires on December 31, 2019.

During the nine months ended June 30, 2019 and 2018, respectively, the Company decreased Accounts Payable by approximately $3.2 million and $2.8 million through the sale of 808,769 and 1,538,129 shares, respectively, by Ergomed.

The following table summarizes the Other Non-Operating Gains (Loss) for the nine and three months ended June 30, 2019 and 2018 relating to these agreements:

	Nine Months Ended		Three Months Ended
	6/30/2019	6/30/2018	6/30/2019	6/30/2018
Amount realized through the sale of shares	$3,167,197	$2,785,932	$1,455,844	$1,560,641
Fair value of shares upon issuance	1,290,000	2,957,400	-	1,710,000
Other non-operating gain (loss)	$1,877,197	$(171,468)	$1,455,844	$( 149,359)

As of June 30, 2019, Ergomed holds 45,226 shares and may sell the shares or return the shares to the Company for cancellation until December 31, 2019.

Incentive Stock Bonus Plan

During the nine and three months ended June 30, 2019, respectively, 7,500 and 4,000 shares of common stock issued from the 2014 Incentive Stock Bonus Plan were forfeited.

FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:

●

Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets

●

Level 3 – Unobservable inputs that reflect management’s assumptions

For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2019:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$-	$-	$10,732,830	$10,732,830

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2018:

	Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)	Total

Derivative instruments	$33	$-	$9,317,031	$9,317,064

The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended June 30, 2019 and the year ended September 30, 2018:

	Nine Months	Year Ended
	Ended	September 30,
	June 30, 2019	2018

Beginning balance	$9,317,031	$2,020,629
Issuances	-	-
Exercises	(1,900,618)	(595,780)
Realized and unrealized (gains) and losses	3,316,417	7,892,182
Ending balance	$10,732,830	$9,317,031

The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

RELATED PARTY TRANSACTIONS

During the quarter ended June 30, 2019, the Company received security purchase agreements from five officers and directors of the Company for the purchase of 30,612 restricted shares of the Company’s common stock. The shares were sold at the aggregate fair market value on the closing date of approximately $210,000. Also during the current quarter, the Company’s CEO purchased 6,631 shares of restricted common stock for $25,000.

COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $30.3 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $10.2 million. During the nine months ended June 30, 2019 and 2018, the Company recorded, net of Ergomed’s discount, approximately $2.2 million and $2.4 million, respectively, as research and development expense related to Ergomed’s services. During the three months ended June 30, 2019 and 2018, the Company recorded, net of Ergomed’s discount, approximately $0.7 million and $0.8 million, respectively, as research and development expense related to Ergomed’s services.

Lease Agreements

The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements, of which $3.2 million is being refunded during years nine through twenty through reduced rental payments. The landlord paid approximately $11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building in service in October 2008.

The Company was deemed to be the owner of the building for accounting purpose under the build-to-suit guidance in ASC 840-40-55. In addition to tenant improvements the Company incurred, the Company also recorded an asset for tenant-directed improvements and for the costs paid by the lessor to purchase the building and to perform improvements, as well as a corresponding liability for the landlord costs. Upon completion of the improvements, the Company did not meet the “sale-leaseback” criteria under ASC 840-40-25, Accounting for Lease, Sale-Leaseback Transactions, and therefore, treated the lease as a financing obligation. Thus, the asset and corresponding liability were not de-recognized. As of June 30, 2019 and September 30, 2018, the leased building asset has a net book value of approximately $15.7 and $16.1 million, respectively, and the landlord liability has a balance of approximately $13.5 million and $13.4 million, respectively. The leased building is being depreciated using a straight-line method over the 20-year lease term to a residual value. The landlord liability is being amortized over the 20 years using the effective interest method. Lease payments allocated to the landlord liability are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.

The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets at June 30, 2019 and September 30, 2018.

Approximate future minimum lease payments under the San Tomas lease as of June 30, 2019 are as follows:

Three months ending September 30, 2019	$453,000
Year ending September 30,
2020	1,872,000
2021	1,937,000
2022	2,004,000
2023	2,073,000
2024	2,145,000
Thereafter	9,540,000
Total future minimum lease obligation	20,024,000
Less imputed interest on financing obligation	(6,548,000)
Net present value of lease financing obligation	$13,476,000

The Company subleases a portion of its rental space on a month-to-month term lease, which requires a 30-day notice for termination. The sublease rental income for the nine months ended June 30, 2019 and 2018 was approximately $55,000 and $53,000, respectively. The sublease rental income for each of the three months ended June 30, 2019 and 2018 was approximately $18,000.

The Company leases its research and development laboratory under a 60-month lease which expires February 28, 2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60-month term of the lease at the rate of approximately $13,000 per month. As of June 30, 2019 and September 30, 2018, the Company has recorded a deferred rent liability of approximately $14,000 and $12,000, respectively.

The Company leases its office headquarters under a 60-month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60-month term of the lease at the rate approximately $8,000 per month. As of June 30, 2019 and September 30, 2018, the Company has recorded a deferred rent liability of approximately $9,000 and $14,000, respectively.

As of June 30, 2019, material contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:

Three months ending September 30, 2019	$66,000
Year ending September 30,
2020	238,000
2021	163,000
2022	69,000
Total	$536,000

The Company leases office equipment under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment is $505. The lease bears interest at an annual interest rate of 6.25%.

.PATENTS

During the nine months ended June 30, 2019 and 2018, no patent impairment charges were recorded. For the nine and three months ended June 30, 2019, amortization of patent costs totaled approximately $72,000 and $49,000, respectively. For the nine and three months ended June 30, 2018, amortization of patent costs totaled approximately $53,000 and $34,000, respectively. Approximate estimated future amortization expense is as follows:

Three months ending September 30, 2019	$11,000
Year ending September 30,
2020	43,000
2021	40,000
2022	36,000
2023	26,000
2024	21,000
Thereafter	95,000
Total	$272,000

LOSS PER COMMON SHARE

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:

	2019	2018

Options and Warrants	7,742,857	12,567,982
Unvested Restricted Stock	552,000	312,000
Total	8,294,857	12,879,982

SUBSEQUENT EVENTS

Between July 1, 2019 and August 13, 2019, the Company received approximately $2.6 million through the exercise of options and warrants to purchase shares of the Company’s common stock.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Liquidity and Capital Resources

The Company’s lead investigational therapy, Multikine® (Leukocyte Interleukin, Injection), is cleared for a Phase 3 clinical trial in advanced primary head and neck cancer by the regulators in twenty-four countries, including the U.S.

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in this report as Multikine. Multikine is the trademark that the Company has registered for this investigational therapy, and this proprietary name is subject to FDA review under the Company’s future anticipated regulatory submission for approval. Multikine has not been licensed or approved by the FDA or any other regulatory agency. Neither has its safety or efficacy been established for any use.

The Company also owns and is developing a pre-clinical technology called LEAPS (Ligand Epitope Antigen Presentation System).

All the Company’s projects are under development. Consequently, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Since inception, the Company has financed its operations through the sale of equity securities, convertible notes, loans and certain research grants. The Company’s expenses will continue to exceed its revenues as it continues the development of Multikine and brings other drug candidates into clinical trials. Until the Company becomes profitable, any or all of these financing vehicles or others may be utilized to assist in funding the Company’s capital requirements.

Capital raised by the Company has been expended primarily for patent applications, research and development, administrative costs, and the construction of the Company’s manufacturing and laboratory facilities. The Company does not anticipate realizing significant revenues until it enters into licensing arrangements for its technology and know-how or until it receives regulatory approval to sell its products (which could take several years). Thus, the Company has been dependent upon the proceeds from the sale of its securities to meet all its liquidity and capital requirements and anticipates having to do so in the future.

The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts. The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company has been receiving millions of dollars from warrant exercises in the past 12 months. It has received approximately another $2.6 million since July 1, 2019. The Company is being funded through these warrant exercises. Should those warrant exercises stop, the Company will explore other sources of funding, to finance operations over the next 12 months. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.

Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $54.7 million as of June 30, 2019 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $5.6 million for the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available from the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by the rate of death accumulation in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.

The Company uses two CRO’s to manage the global Phase 3 study; ICON and Ergomed, who are both international leaders in managing oncology trials. As of September 2016, the study was fully enrolled with 928 patients.

Under a co-development agreement, Ergomed agreed to contribute up to $12 million towards the study where it will perform clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specified maximum amount. Approximately $10.2 million of these credits were realized as of June 30, 2019.

During the nine months ended June 30, 2019, the Company’s cash decreased by approximately $0.8 million. Significant components of this decrease included net cash used to fund the Company’s regular operations, including its Phase 3 clinical trial, of approximately $12.4 million and approximately $0.3 million to purchase long term assets. The decrease was offset by net proceeds from the exercise of warrants of approximately $11.7 million and employee stock purchases of approximately $0.2 million. During the nine months ended June 30, 2018, the Company’s cash remained constant. Cash used in operations of approximately $9.1 million was offset by approximately $9.1 million in cash provided by financing activities. Sources of financing during the nine months included approximately $7.0 million in proceeds from the issuance of common stock and warrants and $2.1 million in proceeds from the exercise of warrants.

During the nine months ended June 30, 2019, 5,836,724 warrants were exercised at a weighted average exercise price of $2.00 for proceeds of approximately $11.7 million. These exercises include 4,014,109 warrants exercised during the three months ended June 30, 2019 for proceeds of approximately $8.4 million. During the nine and three months ended June 30, 2018, 1,117,644 warrants were exercised at a weighted averaged exercise price of $1.91 for proceeds of approximately $2.1 million.

The Company has entered into several Securities Purchase Agreements (SPAs) with Ergomed plc, one of its Clinical Research Organizations responsible for managing the Phase 3 clinical trial, to facilitate a partial payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock in exchange for Ergomed’s agreement to provisionally forbear collection of the payables in an amount equal to the net proceeds from the sale of the shares issued to Ergomed. During the nine months ended June 30, 2019 and 2018, respectively, the Company decreased Accounts Payable by approximately $3.2 million and $2.8 million from the sale of 808,769 and 1,538,129 shares by Ergomed. As of June 30, 2019, Ergomed holds 45,226 shares and may sell the shares or return the shares to the Company for cancellation until December 31, 2019. For more information regarding the SPAs refer to Note C above.

Inventory at June 30, 2019 increased by approximately $110,000 as compared to September 30, 2018. In addition, receivables remained constant, and consist primarily of amounts due from the Company’s partners for reimbursed clinical study costs related to its Phase 3 clinical trial and amounts to be reimbursed for costs related to its Small Business Innovation Research (SBIR) grant.

Results of Operations and Financial Condition

During the nine months ended June 30, 2019, research and development expenses increased by approximately $0.2 million compared to the nine months ended June 30, 2018. During the three months ended June 30, 2019, research and development expenses decreased by approximately $0.1 million compared to the three months ended June 30, 2018. The majority of the Company’s research and development expense relates to its on-going Phase 3 clinical trial. The Company is continuing the Phase 3 clinical trial and research and development expenses fluctuate based on the activity level of the clinical trial.

During the nine and three months ended June 30, 2019, general and administrative expenses increased by approximately $1.2 million and $1.3 million compared to the nine and three months ended June 30, 2018. The increase over the nine month period is primarily due to an increase in public relations costs of approximately $0.8 million, of which approximately $0.3 million relates to equity based compensation. The increase in equity based public relations cost is primarily the result of the timing of the expense recognized with the timing of the services provided. In addition, the nine month period increase is due to an increase in employee stock based compensation of approximately $0.4 million as a result of employee stock options granted during the quarter ended June 30, 2019. The increase for the three months ended June 30, 2019 is primarily due to, the previously mentioned, employee stock based compensation from the grant of the employee stock options during the quarter ended June 30, 2019.

The loss on derivative instruments of approximately $3.3 million and $7.9 million for the nine and three months ended, respectively, is the result of the change in fair value of the derivative liabilities during the respective periods. The gain on derivative instruments of approximately $0.2 million for the nine months ended June 30, 2018 and the de minimus loss on derivative instruments for the three months ended June 30, 2018 were the result of the change in fair value of the derivative liabilities during the respective quarters. These changes were caused mainly by fluctuation in the share price of the Company’s common stock.

Other non-operating gain (loss) for the nine and three months ended June 30, 2019 and 2018 is a result of shares issued to Ergomed to facilitate partial payments of amounts due to Ergomed under the SPA mentioned above. For more information regarding the SPAs refer to Note C above.

Net interest expense decreased by approximately $2.4 million for the nine months ended June 30, 2019 compared to the nine months ended June 30, 2018. Net interest expense decreased by approximately $1.3 million for the three months ended June 30, 2019 compared to the three months ended June 30, 2018. The prior periods included interest expense and the amortization of a discount on the notes payable that were converted by September 30, 2018.

Research and Development Expenses

The Company’s research and development efforts involve Multikine and LEAPS. The table below shows the research and development expenses associated with each project.

	Nine months ended June 30,		Three months ended June 30,
	2019	2018	2019	2018
MULTIKINE	$7,389,101	$7,210,355	$2,131,154	$2,220,634
LEAPS	567,102	503,518	167,401	204,928
TOTAL	$7,956,203	$7,713,873	$2,298,555	$2,425,562

Clinical and other studies necessary to obtain regulatory approval of a new drug involve significant costs and require several years to complete. The extent of the Company’s clinical trials and research programs are primarily based upon the amount of capital available to the Company and the extent to which the Company has received regulatory approvals for clinical trials. The inability of the Company to conduct clinical trials or research, whether due to a lack of capital or regulatory approval, will prevent the Company from completing the studies and research required to obtain regulatory approval for any products which the Company is developing. Without regulatory approval, the Company will be unable to sell any of its products. Since all the Company’s projects are under development, the Company cannot predict when it will be able to generate any revenue from the sale of any of its products.

Critical Accounting Estimates and Policies

Management’s discussion and analysis of the Company’s financial condition and results of operations is based on its unaudited condensed financial statements. The preparation of these financial statements is based on the selection of accounting policies and the application of significant accounting estimates, some of which require management to make judgments, estimates and assumptions that affect the amounts reported in the financial statements and notes. The Company believes some of the more critical estimates and policies that affect its financial condition and results of operations are in the areas of operating leases and stock-based compensation. For more information regarding the Company’s critical accounting estimates and policies, see Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended September 30, 2018. The application of these critical accounting policies and estimates has been discussed with the Audit Committee of the Company’s Board of Directors.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

The Company does not believe that it has any significant exposures to market risk.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the direction and with the participation of the Company’s management, including the Company’s Chief Executive and Chief Financial Officer, the Company has conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures as of June 30, 2019. The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in its periodic reports with the Securities and Exchange Commission is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and regulations, and that such information is accumulated and communicated to the Company’s management, including its principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. The Company’s disclosure controls and procedures are designed to provide a reasonable level of assurance of reaching its desired disclosure control objectives. Based on the evaluation, the Chief Executive and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2019.

Changes in Internal Control over Financial Reporting

There was no change in the Company’s internal control over financial reporting that occurred during the quarter ended June 30, 2019 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

PART II

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the nine months ended June 30, 2019 the Company issued 161,058 restricted shares of common stock to consultants for investor relations services.

The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 with respect to the issuance of these shares. The individuals who acquired these shares were sophisticated investors and were provided full information regarding the Company’s business and operations. There was no general solicitation in connection with the offer or sale of these securities. The individuals who acquired these shares acquired them for their own accounts. The certificates representing these shares bear a restricted legend which provides they cannot be sold except pursuant to an effective registration statement or an exemption from registration. No commission or other form of remuneration was given to any person in connection with the issuance of these shares.

ITEM 6. Exhibits

Number Exhibit

Rule 13a-14(a) Certifications

Section 1350 Certifications

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	CEL-SCI CORPORATION

Date: August 14, 2019	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer*

* Also signing in the capacity of the Principal Accounting and Financial Officer.

EX-31 2 cvm_ex31.htm CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF THE SARBANES-OXLY ACT OF 2002 Blueprint

EXHIBIT 31

CERTIFICATIONS

I, Geert Kersten, certify that:

I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, considering the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects, the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or cause such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of the internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

August 14, 2019	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive Officer

CERTIFICATIONS

I, Geert Kersten, certify that:

I have reviewed this quarterly report on Form 10-Q of CEL-SCI Corporation;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

b) any fraud, whether or not material, that involves management or other employees who have significant role in the registrant’s internal control over financial reporting.

August 14, 2019	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Financial Officer

EX-32 3 cvm_ex32.htm CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Blueprint

EXHIBIT 32

In connection with the Quarterly Report of CEL-SCI Corporation (the “Company”) on Form 10-Q for the period ended June 30, 2019 as filed with the Securities and Exchange Commission (the “Report”), Geert Kersten, the Principal Executive and Financial Officer of the Company, certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.

August 14, 2019	By:	/s/ Geert Kersten
		Geert Kersten
		Principal Executive and Principal Financial Officer

EX-101.INS 4 cvm-20190630.xml XBRL INSTANCE DOCUMENT 0000725363 2019-06-30 0000725363 2018-10-01 2019-06-30 0000725363 2018-09-30 0000725363 CVM:SeriesWMember 2019-06-30 0000725363 CVM:SeriesVMember 2019-06-30 0000725363 CVM:ConsultantsMember 2019-06-30 0000725363 CVM:IncentiveStockOptionPlansMember 2019-06-30 0000725363 CVM:NonQualifiedStockOptionPlansMember 2019-06-30 0000725363 CVM:StockBonusPlansMember 2019-06-30 0000725363 us-gaap:StockCompensationPlanMember 2019-06-30 0000725363 CVM:SeriesNMember 2018-10-01 2019-06-30 0000725363 CVM:ConsultantsMember 2018-10-01 2019-06-30 0000725363 2017-09-30 0000725363 CVM:SeriesVMember 2018-10-01 2019-06-30 0000725363 CVM:IncentiveStockBonusPlansMember 2019-06-30 0000725363 2017-10-01 2018-09-30 0000725363 CVM:IncentiveStockOptionPlansMember 2018-09-30 0000725363 CVM:NonQualifiedStockOptionPlansMember 2018-09-30 0000725363 CVM:StockBonusPlansMember 2018-09-30 0000725363 us-gaap:StockCompensationPlanMember 2018-09-30 0000725363 CVM:IncentiveStockBonusPlansMember 2018-09-30 0000725363 CVM:SeriesXMember 2019-06-30 0000725363 CVM:SeriesWMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesYMember 2019-06-30 0000725363 CVM:SeriesYMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesNMember 2019-06-30 0000725363 CVM:SeriesXMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesZMember 2019-06-30 0000725363 CVM:SeriesZzMember 2019-06-30 0000725363 CVM:SeriesBbMember 2019-06-30 0000725363 CVM:SeriesFfMember 2019-06-30 0000725363 CVM:SeriesCcMember 2019-06-30 0000725363 CVM:SeriesAaMember 2019-06-30 0000725363 CVM:SeriesZMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesZzMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesBbMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesFfMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesCcMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesAaMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesHhMember 2019-06-30 0000725363 CVM:SeriesJjMember 2019-06-30 0000725363 CVM:SeriesIiMember 2019-06-30 0000725363 CVM:SeriesHhMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesJjMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesIiMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesLlMember 2019-06-30 0000725363 CVM:SeriesMmMember 2019-06-30 0000725363 CVM:SeriesLlMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesMmMember 2018-10-01 2019-06-30 0000725363 2017-10-01 2018-06-30 0000725363 us-gaap:FairValueInputsLevel1Member 2019-06-30 0000725363 us-gaap:FairValueInputsLevel2Member 2019-06-30 0000725363 us-gaap:FairValueInputsLevel3Member 2019-06-30 0000725363 us-gaap:FairValueInputsLevel1Member 2018-09-30 0000725363 us-gaap:FairValueInputsLevel2Member 2018-09-30 0000725363 us-gaap:FairValueInputsLevel3Member 2018-09-30 0000725363 CVM:SeriesNnMember 2019-06-30 0000725363 CVM:SeriesNnMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesOoMember 2019-06-30 0000725363 CVM:SeriesOoMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesRrMember 2019-06-30 0000725363 CVM:SeriesRrMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesSsMember 2019-06-30 0000725363 CVM:SeriesSsMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesPpMember 2019-06-30 0000725363 CVM:SeriesPpMember 2018-10-01 2019-06-30 0000725363 CVM:HeadquartersMember 2019-06-30 0000725363 CVM:HeadquartersMember 2018-09-30 0000725363 CVM:ResearchAndDevelopmentLabMember 2019-06-30 0000725363 CVM:ResearchAndDevelopmentLabMember 2018-09-30 0000725363 us-gaap:OptionMember 2018-10-01 2019-06-30 0000725363 us-gaap:OptionMember 2017-10-01 2018-06-30 0000725363 us-gaap:RestrictedStockMember 2018-10-01 2019-06-30 0000725363 us-gaap:RestrictedStockMember 2017-10-01 2018-06-30 0000725363 CVM:SeriesTtMember 2019-06-30 0000725363 CVM:SeriesTtMember 2018-10-01 2019-06-30 0000725363 2018-06-30 0000725363 CVM:SeriesUuMember 2019-06-30 0000725363 CVM:SeriesUuMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesWwMember 2019-06-30 0000725363 CVM:SeriesVvMember 2019-06-30 0000725363 CVM:SeriesWwMember 2018-10-01 2019-06-30 0000725363 CVM:SeriesVvMember 2018-10-01 2019-06-30 0000725363 2019-04-01 2019-06-30 0000725363 2018-04-01 2018-06-30 0000725363 us-gaap:CommonStockMember 2017-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2017-09-30 0000725363 us-gaap:RetainedEarningsMember 2017-09-30 0000725363 us-gaap:CommonStockMember 2018-09-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000725363 us-gaap:RetainedEarningsMember 2018-09-30 0000725363 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0000725363 us-gaap:CommonStockMember 2017-10-01 2017-12-31 0000725363 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000725363 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0000725363 us-gaap:CommonStockMember 2018-12-31 0000725363 us-gaap:CommonStockMember 2017-12-31 0000725363 us-gaap:CommonStockMember 2019-06-30 0000725363 us-gaap:CommonStockMember 2018-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2017-10-01 2017-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000725363 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0000725363 us-gaap:RetainedEarningsMember 2017-10-01 2017-12-31 0000725363 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000725363 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0000725363 us-gaap:RetainedEarningsMember 2018-12-31 0000725363 us-gaap:RetainedEarningsMember 2017-12-31 0000725363 us-gaap:RetainedEarningsMember 2019-06-30 0000725363 us-gaap:RetainedEarningsMember 2018-06-30 0000725363 2018-10-01 2018-12-31 0000725363 2017-10-01 2017-12-31 0000725363 2018-12-31 0000725363 2017-12-31 0000725363 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0000725363 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0000725363 us-gaap:CommonStockMember 2019-03-31 0000725363 us-gaap:CommonStockMember 2018-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000725363 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0000725363 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0000725363 us-gaap:RetainedEarningsMember 2018-01-01 2018-03-31 0000725363 us-gaap:RetainedEarningsMember 2019-03-31 0000725363 us-gaap:RetainedEarningsMember 2018-03-31 0000725363 2019-01-01 2019-03-31 0000725363 2018-01-01 2018-03-31 0000725363 2019-03-31 0000725363 2018-03-31 0000725363 2019-08-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares CEL SCI CORP 0000725363 10-Q 2019-06-30 false --09-30 Yes Non-accelerated Filer Q3 2019

0.01

200000

0.01

600000000

false true

28484637

29586422

1670917

272488

258093

15948864

16218851

10592368

11438561

754825

645238

233784

364622

118264

118657

27338333

29585506

25084

33492

126849

126795

9482995

6818458

4227701

9226799

16009

14029

1249835

2498606

761027

764941

122030

205310

2078800

5743913

28484637

29586422

-348878161

-331591614

349683796

331312184

340669

280346

34066914

28034487

34066914

28034487

9000

14000

12000

10732830

9317031

2020629

1900618

595780

10732830

9317064

10732830

9317031

385

115156

456460

493369

23500

385

309526

486497

15410

16000

327267

122221

616500

297230

118590

624000

11903133

28034487

27843327

13258051

34066914

19570468

29951628

16624552

99962

6193237

123558

3036569

138400

6387200

783760

634000

640000

138400

3387200

783760

134000

640000

10732830 9317064 177299 77632 0 656930 64252 88642 660020 660135 44050 58816 0 607228 433091 188921 0 1249287 0 1249287 3699989 1779724 64256 28456 963990 380474 72185 34215 1172626 487767 2131237 999081 1249835 770436 0 33

13475704

13379962

9485495

10310044

2369438

2346650

3316417 7892182

1146304

916

-3336977

-1251734

119031

296298401

-299754409

280346

331312184

-331591614

278435

132581

340669

195706

332775129

300975618

349683796

315217502

-330345712

-305942239

-348878161

-316664942

2707852

-4834040

299517

166246

337449398

307425853

-336793393

-310650374

955522

-3058275

false

386121

297045

108938

86459

14937282

13537567

5319037

4174533

6981079

5823694

3020482

1748971

7956203

7713873

2298555

2425562

-17286547

-16910533

-12084768

-6014568

1245902

-6187830

-12084768

-6014568

1245902

-6187830

-6447681

-4708135

-6447681

-4708135

-1350774

-3739494

-443442

-1786228

1877197

-171468

1455844

-149359

-3316384

187967

-7905519

-8618

54575

52984

18448

17711

-14551161

-13240522

-5210099

-4088074

-0.58

-1.17

-0.37

-0.36

30046241

14486351

33051888

16651297

-12433594

-9144694

-2544

4819

-3914

548982

-113280

-74856

-3567182

-1960438

150000

109587

-44364

-11047

-122627

-393

-98829

95742 125044

1956424

0 471157 1290000 2957400

108485

109073

36361

36673

123

190

399

35118

35690

36318

36274

35241

35880

104

259

36779

36261

36883

36520

2626311

2193402

0 80716

688070

349319

513028

485710

-286797

-3452

115476

2437

171321

1015

11895842

9125358

3811

5082

234997

97290

11657590

2133677

90224

94773

7091536

-824549

-22788

2294300

-119791 113786

8010

1900618 784119

1355676

1312664

Basis of Presentation   The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2018.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2019 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2018 is derived from the September 30, 2018 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements. The results of operations for the nine and three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire year.   The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations, which are expected for the foreseeable future, and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.   Summary of Significant Accounting Policies:   Research and Office Equipment and Leasehold Improvements – The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.   Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.   Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.   Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of June 30, 2019 and September 30, 2018.   On December 22, 2017, the “Tax Cuts and Jobs Act” (the “Tax Act"), was signed into law by the President of the United States (U.S.). The Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks. The Company has accounted for the income tax effects of the Act in applying FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred income tax asset, there was no impact to the amounts reported in the Company’s financial statements resulting from the Tax Act.   Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.   Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease.  The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense.  For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.   Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's balance sheet.   Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as an expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.   New Accounting Pronouncements   In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), (“ASU 2018-7”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, non-employee share-based payments would be measured at the grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure awards that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company’s financial position and results of operations.   In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (except of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented.  As permitted by the guidance, the Company has an option to retain the original lease classification and historical accounting for initial direct costs for leases existing prior to the adoption date. Furthermore, the Company will not have to reassess contracts entered into prior to the adoption date for the existence of a lease. The Company also has an option not to restate prior periods for the impact of the adoption of the new standard and may instead recognize a cumulative-effect adjustment to beginning retained earnings as of October 1, 2019 for any prior period income statement effects identified. The Company is evaluating the effect that adoption of this new standard will have on the Company’s financial statements and related disclosures.   The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

The Company has incurred significant costs since its inception for the acquisition of certain patented and unpatented proprietary technology and know-how relating to the human immunological defense system, patent applications, research and development, administrative costs, construction of laboratory facilities, and clinical trials.  The Company has funded such costs with proceeds from loans and the public and private sale of its common stock.  The Company will be required to raise additional capital or find additional long-term financing to continue with its research efforts.  The ability to raise capital may be dependent upon market conditions that are outside the control of the Company. The ability of the Company to complete the necessary clinical trials and obtain FDA approval for the sale of products to be developed on a commercial basis is uncertain. Ultimately, the Company must complete the development of its products, obtain the appropriate regulatory approvals and obtain sufficient revenues to support its cost structure. The Company is taking cost-cutting initiatives, as well as exploring other sources of funding, to finance operations over the next 12 months. The Company believes that there is a high likelihood that it will continue to receive funds from warrant exercises similar to the way it has received funds during the past 12 months. However, there can be no assurance that the Company will be able to raise sufficient capital to support its operations.   The Company is currently in the final stages of its large multi-national Phase 3 clinical trial for head and neck cancer with its partners TEVA Pharmaceuticals and Orient Europharma. To finance the study beyond the next twelve months, the Company plans to raise additional capital in the form of corporate partnerships, debt issuances and/or equity financings. The Company believes that it will be able to obtain additional financing because it has done so consistently in the past. However, there can be no assurance that the Company will be successful in raising additional funds on a timely basis or that the funds will be available to the Company on acceptable terms or at all.  If the Company does not raise the necessary amounts of money, it may have to curtail its operations until it can raise the required funding.   The financial statements have been prepared assuming the Company will continue as a going concern, but due to the Company’s recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.   Since the Company launched its Phase 3 clinical trial for Multikine, the Company has incurred expenses of approximately $54.7 million as of June 30, 2019 on direct costs for the Phase 3 clinical trial. The Company estimates it will incur additional expenses of approximately $5.6 million for the remainder of the Phase 3 clinical trial. It should be noted that this estimate is based only on the information currently available in the Company’s contracts with the Clinical Research Organizations responsible for managing the Phase 3 clinical trial and does not include other related costs, e.g., the manufacturing of the drug. This number may be affected by the rate of death accumulation in the study, foreign currency exchange rates, and many other factors, some of which cannot be foreseen today. It is therefore possible that the cost of the Phase 3 clinical trial will be higher than currently estimated.   Nine hundred twenty-eight (928) head and neck cancer patients have been enrolled and have completed treatment in the Phase 3 study. The study end point is a 10% increase in overall survival of patients between the two main comparator groups in favor of the group receiving the Multikine treatment regimen. The determination if the study end point has been met will occur when there are a total of 298 deaths in those two groups.

The changes in stockholders’ equity during the nine months ended June 30, 2019 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Additional</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Common</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Stock</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Paid-In</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">BALANCES AT OCTOBER 1, 2018</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">28,034,487</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">280,346</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">331,312,184</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(331,591,614</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">916</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">298,682</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,987</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">646,766</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">649,753</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">12,279</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">123</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,118</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,241</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">62,784</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">628</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">201,752</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">202,380</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Shares returned for settlement of clinical research costs</td> <td> </td> <td> </td> <td style="text-align: right">(564,905</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(5,649</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">5,649</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">573,660</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">573,660</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net income</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,245,902</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,245,902</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT DECEMBER 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">27,843,327</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">278,435</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">332,775,129</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(330,345,712</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,707,852</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">1,523,933</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,239</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,640,395</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,655,634</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">10,419</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">104</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,779</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,883</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">77,449</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">774</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">224,855</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">225,629</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">(3,500</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(35</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">530,865</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">530,830</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Shares issued for settlement of clinical research costs</td> <td> </td> <td> </td> <td style="text-align: right">500,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,285,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,290,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issuance costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(43,625</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(43,625</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Net loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,447,681</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,447,681</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT MARCH 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">29,951,628</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">299,517</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">337,449,398</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(336,793,393</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">955,522</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">4,014,109</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">40,141</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,212,680</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,252,821</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">4,339</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">43</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,318</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,361</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">20,825</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">140,062</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">140,270</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">(4,000</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(40</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,521,861</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,521,821</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Option exercises</td> <td> </td> <td> </td> <td style="text-align: right">42,770</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">428</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">96,862</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">97,290</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Purchase of stock by officers and directors</td> <td> </td> <td> </td> <td style="text-align: right">37,243</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">372</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">234,625</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">234,997</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issuance costs</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(8,010</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(8,010</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Net loss</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(12,084,768</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(12,084,768</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT JUNE 30, 2019</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">34,066,914</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">340,669</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">349,683,796</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(348,878,161</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1,146,304</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The changes in stockholders’ deficit during the nine months ended June 30, 2018 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Additional</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> Common</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Stock</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Paid-In</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center">Accumulated</td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Amount</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Capital</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Deficit</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 40%">BALANCES AT OCTOBER 1, 2017</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">11,903,133</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">119,031</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">296,298,401</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(299,754,409</td> <td style="width: 1%">)</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(3,336,977</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Sale of common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,289,478</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">12,895</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,437,105</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,450,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">18,984</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">190</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,690</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">35,880</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">13,705</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">137</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,270</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,407</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,448,098</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,448,098</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Warrants issued with notes payable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">656,382</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">656,382</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Conversion of notes payable to common stock</td> <td> </td> <td> </td> <td style="text-align: right">32,751</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">328</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">74,672</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">75,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,187,830</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,187,830</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT DECEMBER 31, 2017</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">13,258,051</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">132,581</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">300,975,618</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(305,942,239</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,834,040</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Sale of common stock</td> <td> </td> <td> </td> <td style="text-align: right">2,501,145</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">25,011</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,652,130</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">4,677,141</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">25,901</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">259</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,261</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,520</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">124,082</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,241</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">227,254</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">228,495</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">279,817</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">279,817</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Conversion of notes payable to common stock</td> <td> </td> <td> </td> <td style="text-align: right">55,373</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">554</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">108,746</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">109,300</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Shares issued for settlement of clinical research costs</td> <td> </td> <td> </td> <td style="text-align: right">660,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,600</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,240,800</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,247,400</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issuance cost</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(94,773</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">(94,773</td> <td>)</td></tr> <tr style="vertical-align: bottom"> <td>Net loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,708,135</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(4,708,135</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT MARCH 31, 2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">16,624,552</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">166,246</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">307,425,853</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(310,650,374</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(3,058,275</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Warrant exercises</td> <td> </td> <td> </td> <td style="text-align: right">1,117,644</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,177</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,906,619</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,917,796</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>401(k) contributions paid in common stock</td> <td> </td> <td> </td> <td style="text-align: right">39,862</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">399</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,274</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36,673</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock issued to nonemployees for services</td> <td> </td> <td> </td> <td style="text-align: right">81,604</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">816</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">208,387</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">209,203</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Equity based compensation - employees</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">465,487</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">465,487</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Conversion of notes payable and interest to common stock</td> <td> </td> <td> </td> <td style="text-align: right">1,106,806</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">11,068</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,179,648</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,190,716</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Shares issued for settlement of clinical research costs</td> <td> </td> <td> </td> <td style="text-align: right">600,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,704,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,710,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Warrants issued with notes payable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">291,234</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">291,234</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Net loss</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,014,568</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,014,568</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>BALANCES AT JUNE 30, 2018</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">19,570,468</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">195,706</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">315,217,502</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(316,664,942</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(1,251,734</td> <td style="padding-bottom: 3pt">)</td></tr> </table>   Underlying share information for equity compensation plans as of June 30, 2019 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Incentive Stock Options Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">138,400</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">99,962</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">385</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">6,387,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,193,237</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">115,156</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">783,760</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,267</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">456,460</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">634,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">122,221</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">493,369</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">640,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">616,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,500</td> <td> </td></tr> </table>   Underlying share information for equity compensation plans as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Incentive Stock Option Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">138,400</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">123,558</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">385</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,387,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,036,569</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">309,526</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">783,760</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">297,230</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">486,497</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">134,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">118,590</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,410</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">640,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">624,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">16,000</td> <td> </td></tr> </table>   Stock option activity: <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,268,862</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,858,108</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">42,770</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">29,322</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,395</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">63,698</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,393</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,268,362</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,847,808</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">42,770</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">26,922</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,016</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">39,505</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table>   During the quarter ended June 30, 2019, the Company adopted the 2019 Stock Compensation Plan, which authorized the issuance of up to 500,000 shares of common stock to officers, directors, employees and consultants.   Employee stock based compensation expense includes the expense related to options issued or vested and restricted stock. Non-employee expense includes the expense related to options and stock issued to consultants expensed over the period of their service contracts. Stock based compensation expense is included in general and administrative expenses on the statements of operations.   Non-employee stock based compensation expense includes the value of shares and options issued under consulting arrangements. At June 30, 2019 and September 30, 2018, approximately $88,000 and $207,000, respectively, are included in prepaid expenses.   Warrants and Non-Employee Options   The following chart represents the warrants and non-employee options outstanding at June 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-right: 7.5pt; text-align: center">Warrant</td> <td> </td> <td style="vertical-align: bottom; padding-right: 18.75pt; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid"> Shares Issuable upon Exercise of Warrants</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom"> Expiration Date</td></tr> <tr> <td style="vertical-align: bottom; width: 23%">Series N</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">8/18/2008</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 15%; text-align: right">85,339</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 15%; text-align: right">3.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">2/18/2020</td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">810,127</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">19.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/2020</td></tr> <tr> <td style="vertical-align: bottom">Series UU</td> <td> </td> <td style="vertical-align: bottom; text-align: right">6/11/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">163,544</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.80</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/11/2020</td></tr> <tr> <td style="vertical-align: bottom">Series W</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/28/2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">688,930</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">16.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/28/2020</td></tr> <tr> <td style="vertical-align: bottom">Series X</td> <td> </td> <td style="vertical-align: bottom; text-align: right">1/13/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">120,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">9.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/13/2021</td></tr> <tr> <td style="vertical-align: bottom">Series Y</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/15/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">26,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">12.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/15/2021</td></tr> <tr> <td style="vertical-align: bottom">Series ZZ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/18/2021</td></tr> <tr> <td style="vertical-align: bottom">Series BB</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/26/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/22/2021</td></tr> <tr> <td style="vertical-align: bottom">Series Z</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">264,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11/23/2021</td></tr> <tr> <td style="vertical-align: bottom">Series FF</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/8/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,048</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.91</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/1/2021</td></tr> <tr> <td style="vertical-align: bottom">Series CC</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/8/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">611,463</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">5.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/8/2021</td></tr> <tr> <td style="vertical-align: bottom">Series HH</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/23/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,500</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.13</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/16/2022</td></tr> <tr> <td style="vertical-align: bottom">Series AA</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/26/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">200,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/22/2022</td></tr> <tr> <td style="vertical-align: bottom">Series JJ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">3/14/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">9,450</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.13</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/8/2022</td></tr> <tr> <td style="vertical-align: bottom">Series LL</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/30/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">26,398</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.59</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4/30/2022</td></tr> <tr> <td style="vertical-align: bottom">Series MM</td> <td> </td> <td style="vertical-align: bottom; text-align: right">6/22/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">893,491</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.86</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/22/2022</td></tr> <tr> <td style="vertical-align: bottom">Series NN</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/24/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">473,798</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.52</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/24/2022</td></tr> <tr> <td style="vertical-align: bottom">Series OO</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/31/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">60,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.52</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/31/2022</td></tr> <tr> <td style="vertical-align: bottom">Series II</td> <td> </td> <td style="vertical-align: bottom; text-align: right">3/14/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">95,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">9/14/2022</td></tr> <tr> <td style="vertical-align: bottom">Series RR</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/30/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">495,326</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.65</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/30/2022</td></tr> <tr> <td style="vertical-align: bottom">Series SS</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/19/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">514,476</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.09</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/18/2022</td></tr> <tr> <td style="vertical-align: bottom">Series TT</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/5/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">760,758</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.24</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/5/2023</td></tr> <tr> <td style="vertical-align: bottom">Series PP</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/28/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">112,500</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.30</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/28/2023</td></tr> <tr> <td style="vertical-align: bottom">Series WW</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/2/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,950</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.63</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/28/2023</td></tr> <tr> <td style="vertical-align: bottom">Series VV</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/2/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">90,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/2/2024</td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/28/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/27/2027</td></tr> </table>   The table below presents the fair value of the warrant liabilities at the balance sheet dates:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> June 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> September 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,835</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">770,436</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,131,237</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">999,081</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,172,626</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">487,767</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">72,185</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34,215</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">963,990</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">380,474</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">64,256</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">28,456</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,699,989</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,779,724</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">433,091</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">188,921</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">607,228</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">44,050</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">58,816</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">660,020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">660,135</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">64,252</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">88,642</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">656,930</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">177,299</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">77,632</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">10,732,830</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">9,317,064</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019 </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018 </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(756,261</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">(479,399</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">22,842</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">(1,132,156</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">18,478</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">(684,859</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">34,682</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(37,970</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">2,103</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">(583,516</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">28,337</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">(35,800</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,988</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">(2,007,287</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">181,244</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,492</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,492</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">(244,170</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">23,119</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">195,228</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">170,131</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">(22,859</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">7,962</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">(593,960</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">250,578</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(32,954</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">11,970</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">(55,622</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">169,808</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(99,667</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">10,002</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net (loss) gain on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(3,316,384</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">187,967</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(768,188</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">(974,251</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">26,389</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">(1,748,184</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">42,609</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">(799,690</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">26,587</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(50,608</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,914</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">(676,784</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">19,661</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">(43,536</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,695</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">(2,346,985</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">139,325</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">(278,773</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">15,818</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">88,478</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,712</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">(33,501</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">5,279</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">(709,303</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">199,970</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(48,880</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">7,960</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">(169,089</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">132,884</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(114,413</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,695</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net loss on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(7,905,519</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(8,618</td> <td style="padding-bottom: 3pt">)</td></tr> </table>   The Company reviews all outstanding warrants in accordance with the requirements of ASC 815. This topic provides that an entity should use a two-step approach to evaluate whether an equity-linked financial instrument (or embedded feature) is indexed to its own stock, including evaluating the instrument’s contingent exercise and settlement provisions. The warrant agreements provide for adjustments to the exercise price for certain dilutive events. Under the provisions of ASC 815, the warrants are not considered indexed to the Company’s stock because future equity offerings or sales of the Company’s stock are not an input to the fair value of a “fixed-for-fixed” option on equity shares, and equity classification is therefore precluded.   In accordance with ASC 815, derivative liabilities must be measured at fair value upon issuance and re-valued at the end of each reporting period through expiration. Any change in fair value between the respective reporting dates is recognized as a gain or loss.   Expiration of Derivative Liabilities   On December 10, 2018, 1,360,960 Series DD and 1,360,960 Series EE warrants, with an exercise price of $4.50, expired. The expiration dates of these warrants had been previously extended and such modifications were reflected in the fair value measurements of the warrants on the dates of modification.   On October 11, 2018, 327,729 Series S warrants, with an exercise price of $31.25, expired. The exercise price of these warrants had been previously repriced under temporarily revised terms. During the quarter ended June 30, 2018 and under the revised terms, 709,391 previously outstanding warrants were exercised for total proceeds of approximately $1.2 million,   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 24px">2.</td> <td style="text-align: justify">Securities Purchase Agreements</td></tr> </table>   The Company has entered into several Securities Purchase Agreements (SPAs) with Ergomed plc, one of its Clinical Research Organizations responsible for managing the Phase 3 clinical trial, to facilitate a partial payment of amounts due Ergomed. Under the Agreements, the Company issued Ergomed shares of common stock as a forbearance fee in exchange for Ergomed’s agreement to provisionally forbear collection of the payables in an amount equal to the net proceeds from the sales of the shares issued to Ergomed. Upon issuance, the Company expenses the full value of the shares as Other Non-Operating Gain/Loss and subsequently offsets the expense as amounts are realized through the sale by Ergomed and reduces accounts payable to Ergomed. Any amounts received from the sale of the shares in excess of the payables will be applied towards the satisfaction of any future amounts owed.   On December 31, 2018, the prior SPA expired. Pursuant to that arrangement, Ergomed returned 564,905 unsold shares for cancellation. The par value of those shares was reclassed from Common Stock to Additional Paid-In Capital on the balance sheet.   On January 9, 2019, the Company entered into a new SPA under which it issued Ergomed 500,000 restricted shares of the Company’s common stock valued at approximately $1.3 million. This current SPA expires on December 31, 2019.   During the nine months ended June 30, 2019 and 2018, respectively, the Company decreased Accounts Payable by approximately $3.2 million and $2.8 million through the sale of 808,769 and 1,538,129 shares, respectively, by Ergomed.   The following table summarizes the Other Non-Operating Gains (Loss) for the nine and three months ended June 30, 2019 and 2018 relating to these agreements:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%">Amount realized through the sale of shares</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">3,167,197</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,785,932</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,455,844</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,560,641</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Fair value of shares upon issuance</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,290,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,957,400</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,710,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Other non-operating gain (loss)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1,877,197</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(171,468</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1,455,844</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">( 149,359</td> <td style="padding-bottom: 3pt">)</td></tr> </table>   As of June 30, 2019, Ergomed holds 45,226 shares and may sell the shares or return the shares to the Company for cancellation until December 31, 2019.   <table cellpadding="0" style="width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr> <td style="vertical-align: top; width: 24px">3.</td> <td style="text-align: justify">Incentive Stock Bonus Plan</td></tr> </table>   During the nine and three months ended June 30, 2019, respectively, 7,500 and 4,000 shares of common stock issued from the 2014 Incentive Stock Bonus Plan were forfeited.

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.    ASC 820-10 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to active markets for identical assets and liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The Company classifies fair value balances based on the observability of those inputs. The three levels of the fair value hierarchy are as follows:   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif">● </td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities</td></tr> </table>   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif">● </td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 2 – Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active and amounts derived from valuation models where all significant inputs are observable in active markets</td></tr> </table>   <table cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; width: 60px; padding-left: 27pt; font: 12pt Times New Roman, Times, Serif">● </td> <td style="padding: 0.75pt; font: 12pt Times New Roman, Times, Serif; text-align: justify">Level 3 – Unobservable inputs that reflect management’s assumptions</td></tr> </table>   For disclosure purposes, assets and liabilities are classified in their entirety in the fair value hierarchy level based on the lowest level of input that is significant to the overall fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy levels.   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Quoted Prices in Active Markets for Identical Assets or Liabilities  (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs  (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Unobservable Inputs  (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Derivative instruments</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,732,830</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,732,830</td> <td style="width: 1%"> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Derivative instruments</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">9,317,031</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">9,317,064</td> <td style="width: 1%"> </td></tr> </table>    The following sets forth the reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3) for the three months ended June 30, 2019 and the year ended September 30, 2018:   <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Year Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; font-size: 8pt; text-align: left">Beginning balance</td><td style="width: 8%; font-size: 8pt"> </td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 12%; font-size: 8pt; text-align: right">9,317,031</td><td style="width: 1%; font-size: 8pt; text-align: left"> </td><td style="width: 8%; font-size: 8pt"> </td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 12%; font-size: 8pt; text-align: right">2,020,629</td><td style="width: 1%; font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Issuances</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">—  </td><td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">—  </td><td style="font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Exercises</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">(1,900,618</td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">(595,780</td><td style="font-size: 8pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">Realized and unrealized (gains) and losses</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">3,316,417</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">7,892,182</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; padding-bottom: 2.5pt">Ending balance</td><td style="font-size: 8pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">10,732,830</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">9,317,031</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"> </td></tr> </table>   The fair values of the Company’s derivative instruments disclosed above under Level 3 are primarily derived from valuation models where significant inputs such as historical price and volatility of the Company’s stock, as well as U.S. Treasury Bill rates, are observable in active markets.

During the quarter ended June 30, 2019, the Company received security purchase agreements from five officers and directors of the Company for the purchase of 30,612 restricted shares of the Company’s common stock. The shares were sold at the aggregate fair market value on the closing date of approximately $210,000. Also during the current quarter, the Company’s CEO purchased 6,631 shares of restricted common stock for $25,000.

Clinical Research Agreements    Under co-development and revenue sharing agreements with Ergomed, Ergomed agreed to contribute up to $12 million towards the Company’s Phase 3 Clinical Trial in the form of discounted clinical services in exchange for a single digit percentage of milestone and royalty payments, up to a specific maximum amount. The Company accounted for the co-development and revenue sharing agreements in accordance with ASC 808 “Collaborative Arrangements”. The Company determined the payments to Ergomed are within the scope of ASC 730 “Research and Development.” Therefore, the Company records the discount on the clinical services as a credit to research and development expense on its Statements of Operations. Since the inception of the agreement with Ergomed, the Company has incurred research and development expenses of approximately $30.3 million for Ergomed’s services. This amount is net of Ergomed’s discount of approximately $10.2 million. During the nine months ended June 30, 2019 and 2018, the Company recorded, net of Ergomed’s discount, approximately $2.2 million and $2.4 million, respectively, as research and development expense related to Ergomed’s services. During the three months ended June 30, 2019 and 2018, the Company recorded, net of Ergomed’s discount, approximately $0.7 million and $0.8 million, respectively, as research and development expense related to Ergomed’s services.   Lease Agreements   The Company leases a manufacturing facility near Baltimore, Maryland (the San Tomas lease). The building was remodeled in accordance with the Company’s specifications so that it can be used by the Company to manufacture Multikine for the Company’s Phase 3 clinical trial and sales of the drug if approved by the FDA. The lease is for a term of twenty years and requires annual base rent to escalate each year at 3%. The Company is required to pay all real estate and personal property taxes, insurance premiums, maintenance expenses, repair costs and utilities. The lease allows the Company, at its election, to extend the lease for two ten-year periods or to purchase the building at the end of the 20-year lease. The Company contributed approximately $9.3 million towards the tenant-directed improvements, of which $3.2 million is being refunded during years nine through twenty through reduced rental payments. The landlord paid approximately $11.9 million towards the purchase of the building, land and the tenant-directed improvements. The Company placed the building in service in October 2008.   The Company was deemed to be the owner of the building for accounting purpose under the build-to-suit guidance in ASC 840-40-55. In addition to tenant improvements the Company incurred, the Company also recorded an asset for tenant-directed improvements and for the costs paid by the lessor to purchase the building and to perform improvements, as well as a corresponding liability for the landlord costs. Upon completion of the improvements, the Company did not meet the “sale-leaseback” criteria under ASC 840-40-25, Accounting for Lease, Sale-Leaseback Transactions, and therefore, treated the lease as a financing obligation. Thus, the asset and corresponding liability were not de-recognized. As of June 30, 2019 and September 30, 2018, the leased building asset has a net book value of approximately $15.7 and $16.1 million, respectively, and the landlord liability has a balance of approximately $13.5 million and $13.4 million, respectively. The leased building is being depreciated using a straight-line method over the 20-year lease term to a residual value. The landlord liability is being amortized over the 20 years using the effective interest method. Lease payments allocated to the landlord liability are accounted for as debt service payments on that liability using the finance method of accounting per ASC 840-40-55.   The Company was required to deposit the equivalent of one year of base rent in accordance with the lease. When the Company meets the minimum cash balance required by the lease, the deposit will be returned to the Company. The approximate $1.7 million deposit is included in non-current assets at June 30, 2019 and September 30, 2018.   Approximate future minimum lease payments under the San Tomas lease as of June 30, 2019 are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Three months ending September 30, 2019   </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">453,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2020</td> <td> </td> <td> </td> <td style="text-align: right">1,872,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2021</td> <td> </td> <td> </td> <td style="text-align: right">1,937,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2022</td> <td> </td> <td> </td> <td style="text-align: right">2,004,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2023</td> <td> </td> <td> </td> <td style="text-align: right">2,073,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2024</td> <td> </td> <td> </td> <td style="text-align: right">2,145,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">9,540,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total future minimum lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">20,024,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less imputed interest on financing obligation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,548,000</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Net present value of lease financing obligation</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">13,476,000</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The Company subleases a portion of its rental space on a month-to-month term lease, which requires a 30-day notice for termination. The sublease rental income for the nine months ended June 30, 2019 and 2018 was approximately $55,000 and $53,000, respectively. The sublease rental income for each of the three months ended June 30, 2019 and 2018 was approximately $18,000.   The Company leases its research and development laboratory under a 60-month lease which expires February 28, 2022. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60-month term of the lease at the rate of approximately $13,000 per month. As of June 30, 2019 and September 30, 2018, the Company has recorded a deferred rent liability of approximately $14,000 and $12,000, respectively.   The Company leases its office headquarters under a 60-month lease which expires June 30, 2020. The operating lease includes escalating rental payments. The Company is recognizing the related rent expense on a straight-line basis over the full 60-month term of the lease at the rate approximately $8,000 per month. As of June 30, 2019 and September 30, 2018, the Company has recorded a deferred rent liability of approximately $9,000 and $14,000, respectively.   As of June 30, 2019, material contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 85%">Three months ending September 30, 2019</td> <td style="width: 15%; padding-left: 0.25in; text-align: right"> $66,000</td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td style="padding-left: 0.25in; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2020</td> <td style="padding-left: 0.25in; text-align: right">  238,000</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2021</td> <td style="padding-left: 0.25in; text-align: right">  163,000</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2022</td> <td style="border-bottom: black 1pt solid; padding-left: 0.25in; text-align: right">      69,000</td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="border-bottom: black 1.5pt double; padding-left: 0.25in; text-align: right"> $536,000</td></tr> </table>   The Company leases office equipment under a capital lease arrangement. The term of the capital lease is 60 months and expires on October 31, 2021. The monthly lease payment is $505. The lease bears interest at an annual interest rate of 6.25%.

During the nine months ended June 30, 2019 and 2018, no patent impairment charges were recorded. For the nine and three months ended June 30, 2019, amortization of patent costs totaled approximately $72,000 and $49,000, respectively. For the nine and three months ended June 30, 2018, amortization of patent costs totaled approximately $53,000 and $34,000, respectively. Approximate estimated future amortization expense is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Three months ending September 30, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">11,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2020</td> <td> </td> <td> </td> <td style="text-align: right">43,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2021</td> <td> </td> <td> </td> <td style="text-align: right">40,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2022</td> <td> </td> <td> </td> <td style="text-align: right">36,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2023</td> <td> </td> <td> </td> <td style="text-align: right">26,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2024</td> <td> </td> <td> </td> <td style="text-align: right">21,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">95,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">272,000</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Options and Warrants</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">7,742,857</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">12,567,982</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Unvested Restricted Stock</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">552,000</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">312,000</td> <td style="padding-bottom: 3pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">8,294,857</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double"> </td> <td style="border-bottom: black 1pt double; text-align: right">12,879,982</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

Between July 1, 2019 and August 13, 2019, the Company received approximately $2.6 million through the exercise of options and warrants to purchase shares of the Company’s common stock.

The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2018.   In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2019 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2018 is derived from the September 30, 2018 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements. The results of operations for the nine and three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire year.   The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations, which are expected for the foreseeable future, and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.

Research and Office Equipment and Leasehold Improvements – The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized.  A full valuation allowance was recorded against the deferred tax assets as of June 30, 2019 and September 30, 2018.   On December 22, 2017, the “Tax Cuts and Jobs Act” (the “Tax Act"), was signed into law by the President of the United States (U.S.). The Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks. The Company has accounted for the income tax effects of the Act in applying FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred income tax asset, there was no impact to the amounts reported in the Company’s financial statements resulting from the Tax Act.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease.  The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense.  For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.

Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's balance sheet.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as an expense over the requisite service or vesting period.   Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options.   The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders.   The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period.   Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), (“ASU 2018-7”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, non-employee share-based payments would be measured at the grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure awards that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company’s financial position and results of operations.   In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (except of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented.  As permitted by the guidance, the Company has an option to retain the original lease classification and historical accounting for initial direct costs for leases existing prior to the adoption date. Furthermore, the Company will not have to reassess contracts entered into prior to the adoption date for the existence of a lease. The Company also has an option not to restate prior periods for the impact of the adoption of the new standard and may instead recognize a cumulative-effect adjustment to beginning retained earnings as of October 1, 2019 for any prior period income statement effects identified. The Company is evaluating the effect that adoption of this new standard will have on the Company’s financial statements and related disclosures.   The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

Underlying share information for equity compensation plans as of June 30, 2019 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Incentive Stock Options Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">138,400</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">99,962</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">385</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">6,387,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">6,193,237</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">115,156</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">783,760</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">327,267</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">456,460</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">634,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">122,221</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">493,369</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">640,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">616,500</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,500</td> <td> </td></tr> </table>   Underlying share information for equity compensation plans as of September 30, 2018 is as follows:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> Name of Plan</td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total Shares Reserved Under Plans</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Reserved for Outstanding Options</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Shares Issued</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Remaining Options/Shares Under Plans</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Incentive Stock Option Plans</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">138,400</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">123,558</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">N/A</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">385</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Non-Qualified Stock Option Plans</td> <td> </td> <td> </td> <td style="text-align: right">3,387,200</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">3,036,569</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">309,526</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Bonus Plans</td> <td> </td> <td> </td> <td style="text-align: right">783,760</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">297,230</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">486,497</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Stock Compensation Plan</td> <td> </td> <td> </td> <td style="text-align: right">134,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">118,590</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">15,410</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Incentive Stock Bonus Plan</td> <td> </td> <td> </td> <td style="text-align: right">640,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">N/A</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">624,000</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">16,000</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,268,862</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,858,108</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">42,770</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">29,322</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">26,395</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">63,698</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,393</td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended June 30,</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 75%">Granted</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">3,268,362</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1,847,808</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">42,770</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Expired</td> <td> </td> <td> </td> <td style="text-align: right">26,922</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">2,016</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Forfeited</td> <td> </td> <td> </td> <td style="text-align: right">39,505</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; padding-right: 7.5pt; text-align: center">Warrant</td> <td> </td> <td style="vertical-align: bottom; padding-right: 18.75pt; text-align: center">Issue Date</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid"> Shares Issuable upon Exercise of Warrants</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: center">Exercise Price</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt"> </td> <td style="vertical-align: bottom"> Expiration Date</td></tr> <tr> <td style="vertical-align: bottom; width: 23%">Series N</td> <td style="width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">8/18/2008</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 15%; text-align: right">85,339</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 1%">$</td> <td style="vertical-align: bottom; width: 15%; text-align: right">3.00</td> <td style="vertical-align: bottom; width: 1%"> </td> <td style="vertical-align: bottom; width: 20%; text-align: right">2/18/2020</td></tr> <tr> <td style="vertical-align: bottom">Series V</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/28/2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">810,127</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">19.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/28/2020</td></tr> <tr> <td style="vertical-align: bottom">Series UU</td> <td> </td> <td style="vertical-align: bottom; text-align: right">6/11/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">163,544</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.80</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/11/2020</td></tr> <tr> <td style="vertical-align: bottom">Series W</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/28/2015</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">688,930</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">16.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/28/2020</td></tr> <tr> <td style="vertical-align: bottom">Series X</td> <td> </td> <td style="vertical-align: bottom; text-align: right">1/13/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">120,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">9.25</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/13/2021</td></tr> <tr> <td style="vertical-align: bottom">Series Y</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/15/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">26,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">12.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/15/2021</td></tr> <tr> <td style="vertical-align: bottom">Series ZZ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">20,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">5/18/2021</td></tr> <tr> <td style="vertical-align: bottom">Series BB</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/26/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">16,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">8/22/2021</td></tr> <tr> <td style="vertical-align: bottom">Series Z</td> <td> </td> <td style="vertical-align: bottom; text-align: right">5/23/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">264,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">11/23/2021</td></tr> <tr> <td style="vertical-align: bottom">Series FF</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/8/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">68,048</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.91</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/1/2021</td></tr> <tr> <td style="vertical-align: bottom">Series CC</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/8/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">611,463</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">5.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/8/2021</td></tr> <tr> <td style="vertical-align: bottom">Series HH</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/23/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6,500</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.13</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/16/2022</td></tr> <tr> <td style="vertical-align: bottom">Series AA</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/26/2016</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">200,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">13.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/22/2022</td></tr> <tr> <td style="vertical-align: bottom">Series JJ</td> <td> </td> <td style="vertical-align: bottom; text-align: right">3/14/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">9,450</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.13</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">3/8/2022</td></tr> <tr> <td style="vertical-align: bottom">Series LL</td> <td> </td> <td style="vertical-align: bottom; text-align: right">4/30/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">26,398</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.59</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">4/30/2022</td></tr> <tr> <td style="vertical-align: bottom">Series MM</td> <td> </td> <td style="vertical-align: bottom; text-align: right">6/22/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">893,491</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.86</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/22/2022</td></tr> <tr> <td style="vertical-align: bottom">Series NN</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/24/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">473,798</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.52</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/24/2022</td></tr> <tr> <td style="vertical-align: bottom">Series OO</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/31/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">60,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.52</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/31/2022</td></tr> <tr> <td style="vertical-align: bottom">Series II</td> <td> </td> <td style="vertical-align: bottom; text-align: right">3/14/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">95,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">3.00</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">9/14/2022</td></tr> <tr> <td style="vertical-align: bottom">Series RR</td> <td> </td> <td style="vertical-align: bottom; text-align: right">10/30/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">495,326</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.65</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10/30/2022</td></tr> <tr> <td style="vertical-align: bottom">Series SS</td> <td> </td> <td style="vertical-align: bottom; text-align: right">12/19/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">514,476</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.09</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">12/18/2022</td></tr> <tr> <td style="vertical-align: bottom">Series TT</td> <td> </td> <td style="vertical-align: bottom; text-align: right">2/5/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">760,758</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.24</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/5/2023</td></tr> <tr> <td style="vertical-align: bottom">Series PP</td> <td> </td> <td style="vertical-align: bottom; text-align: right">8/28/2017</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">112,500</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.30</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">2/28/2023</td></tr> <tr> <td style="vertical-align: bottom">Series WW</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/2/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1,950</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.63</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">6/28/2023</td></tr> <tr> <td style="vertical-align: bottom">Series VV</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/2/2018</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">90,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">1.75</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">1/2/2024</td></tr> <tr> <td style="vertical-align: bottom">Consultants</td> <td> </td> <td style="vertical-align: bottom; text-align: right">7/28/17</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">10,000</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom">$</td> <td style="vertical-align: bottom; text-align: right">2.18</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: right">7/27/2027</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> June 30, 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> September 30, 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,835</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">770,436</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">2,131,237</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">999,081</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,172,626</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">487,767</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">72,185</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">34,215</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">963,990</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">380,474</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">64,256</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">28,456</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">3,699,989</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,779,724</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">433,091</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">188,921</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">607,228</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">44,050</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">58,816</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">660,020</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">660,135</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">64,252</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">88,642</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">656,930</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">177,299</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">77,632</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">10,732,830</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">9,317,064</td> <td style="padding-bottom: 3pt"> </td></tr> </table> The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2019 </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">2018 </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(756,261</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">(479,399</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">22,842</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">(1,132,156</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">18,478</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">(684,859</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">34,682</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(37,970</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">2,103</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">(583,516</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">28,337</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">(35,800</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,988</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">(2,007,287</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">181,244</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,492</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">1,249,287</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">5,492</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">(244,170</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">23,119</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">195,228</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">170,131</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">(22,859</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">7,962</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">(593,960</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">250,578</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(32,954</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">11,970</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">(55,622</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">169,808</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(99,667</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">10,002</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net (loss) gain on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(3,316,384</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">187,967</td> <td style="padding-bottom: 3pt"> </td></tr> </table>   The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center"> 2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 76%">Series S warrants</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">(768,188</td> <td style="width: 1%">)</td></tr> <tr style="vertical-align: bottom"> <td>Series V warrants</td> <td> </td> <td> </td> <td style="text-align: right">(974,251</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">26,389</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series W warrants</td> <td> </td> <td> </td> <td style="text-align: right">(1,748,184</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">42,609</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series Z warrants</td> <td> </td> <td> </td> <td style="text-align: right">(799,690</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">26,587</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series ZZ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(50,608</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,914</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series AA warrants</td> <td> </td> <td> </td> <td style="text-align: right">(676,784</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">19,661</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series BB warrants</td> <td> </td> <td> </td> <td style="text-align: right">(43,536</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">1,695</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series CC warrants</td> <td> </td> <td> </td> <td style="text-align: right">(2,346,985</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">139,325</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series DD warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series EE warrants</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">36</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series FF warrants</td> <td> </td> <td> </td> <td style="text-align: right">(278,773</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">15,818</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series GG warrants</td> <td> </td> <td> </td> <td style="text-align: right">88,478</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">132,712</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series HH warrants</td> <td> </td> <td> </td> <td style="text-align: right">(33,501</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">5,279</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series II warrants</td> <td> </td> <td> </td> <td style="text-align: right">(709,303</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">199,970</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series JJ warrants</td> <td> </td> <td> </td> <td style="text-align: right">(48,880</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">7,960</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Series KK warrants</td> <td> </td> <td> </td> <td style="text-align: right">(169,089</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">132,884</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Series LL warrants</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(114,413</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">6,695</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Net loss on warrant liabilities</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(7,905,519</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(8,618</td> <td style="padding-bottom: 3pt">)</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Nine Months Ended</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center">Three Months Ended</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2018</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2019</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">6/30/2018</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 50%">Amount realized through the sale of shares</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">3,167,197</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,785,932</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,455,844</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">1,560,641</td> <td style="width: 2%"> </td></tr> <tr style="vertical-align: bottom"> <td>Fair value of shares upon issuance</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,290,000</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">2,957,400</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">1,710,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Other non-operating gain (loss)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1,877,197</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">(171,468</td> <td style="padding-bottom: 3pt">)</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">1,455,844</td> <td style="padding-bottom: 3pt"> </td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">( 149,359</td> <td style="padding-bottom: 3pt">)</td></tr> </table>

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2019:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Quoted Prices in Active Markets for Identical Assets or Liabilities  (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs  (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Unobservable Inputs  (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Derivative instruments</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,732,830</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">10,732,830</td> <td style="width: 1%"> </td></tr> </table>   The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2018:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Other Observable Inputs (Level 2)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Significant Unobservable Inputs (Level 3)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 52%">Derivative instruments</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">33</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">9,317,031</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">9,317,064</td> <td style="width: 1%"> </td></tr> </table>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Nine Months Ended</td><td style="font-size: 8pt; font-weight: bold"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Year Ended</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">June 30, 2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2018</td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="3" style="text-align: center"> </td><td> </td> <td colspan="3" style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="width: 56%; font-size: 8pt; text-align: left">Beginning balance</td><td style="width: 8%; font-size: 8pt"> </td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 12%; font-size: 8pt; text-align: right">9,317,031</td><td style="width: 1%; font-size: 8pt; text-align: left"> </td><td style="width: 8%; font-size: 8pt"> </td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 12%; font-size: 8pt; text-align: right">2,020,629</td><td style="width: 1%; font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Issuances</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">—  </td><td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">—  </td><td style="font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Exercises</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">(1,900,618</td><td style="font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt"> </td> <td style="font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; text-align: right">(595,780</td><td style="font-size: 8pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">Realized and unrealized (gains) and losses</td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">3,316,417</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">7,892,182</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; padding-bottom: 2.5pt">Ending balance</td><td style="font-size: 8pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">10,732,830</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"> </td><td style="font-size: 8pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">9,317,031</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Three months ending September 30, 2019   </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">453,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2020</td> <td> </td> <td> </td> <td style="text-align: right">1,872,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2021</td> <td> </td> <td> </td> <td style="text-align: right">1,937,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2022</td> <td> </td> <td> </td> <td style="text-align: right">2,004,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2023</td> <td> </td> <td> </td> <td style="text-align: right">2,073,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> 2024</td> <td> </td> <td> </td> <td style="text-align: right">2,145,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 9pt"> Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">9,540,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total future minimum lease obligation</td> <td> </td> <td> </td> <td style="text-align: right">20,024,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td>Less imputed interest on financing obligation</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">(6,548,000</td> <td style="padding-bottom: 1.5pt">)</td></tr> <tr style="vertical-align: bottom"> <td>Net present value of lease financing obligation</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">13,476,000</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 85%">Three months ending September 30, 2019</td> <td style="width: 15%; padding-left: 0.25in; text-align: right"> $66,000</td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td style="padding-left: 0.25in; text-align: right"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2020</td> <td style="padding-left: 0.25in; text-align: right">  238,000</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2021</td> <td style="padding-left: 0.25in; text-align: right">  163,000</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2022</td> <td style="border-bottom: black 1pt solid; padding-left: 0.25in; text-align: right">      69,000</td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="border-bottom: black 1.5pt double; padding-left: 0.25in; text-align: right"> $536,000</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 88%">Three months ending September 30, 2019</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">11,000</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom"> <td>Year ending September 30,</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2020</td> <td> </td> <td> </td> <td style="text-align: right">43,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2021</td> <td> </td> <td> </td> <td style="text-align: right">40,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2022</td> <td> </td> <td> </td> <td style="text-align: right">36,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2023</td> <td> </td> <td> </td> <td style="text-align: right">26,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">2024</td> <td> </td> <td> </td> <td style="text-align: right">21,000</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 27pt">Thereafter</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1pt solid"> </td> <td style="border-bottom: black 1pt solid; text-align: right">95,000</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td>Total</td> <td style="padding-bottom: 3pt"> </td> <td style="border-bottom: black 1pt double">$</td> <td style="border-bottom: black 1pt double; text-align: right">272,000</td> <td style="padding-bottom: 3pt"> </td></tr> </table>

12895

2437105

2450000

25011

4652130

4667141

1289478

2501145

12279

18984

4339

39862

10419

25901

140270

209203

628

137

208

816

201752

25270

140062

208387

202380

25407

774

1241

224855

227254

225629

228495

62784

13705

20825

81604

77449

124082

1521821

465487

-40

573660

1448098

1521861

465487

573660

1448098

-35

530865

279817

530830

279817

2190716

11068

2179648

554

108746

109300

1106806

55373

1710000

-5649

6000

5649

1704000

5000

6600

1285000

1240800

1290000

1247400

-564905

600000

500000

660000

8010

43625

94773

43625

94773

10252821 2917796 2987 40141 11177 646766 10212680 2906619 0 649753 15239 2640395 2655634 298682 4014109 1117644 1523933 -4000 -3500

97290

428

96862

42770

234997 372 234625 37243

291234

3268862

1858108

3268362

1847808

42770 0 42770 0

29322

26395

26922

2016

63698

1393

39505

8/18/2008 7/28/2017 5/28/2015 10/28/2015 2/15/2016 1/13/2016 5/23/2016 5/23/2016 8/26/2016 12/8/2016 12/8/2016 8/26/2016 2/23/2017 3/14/2017 3/14/2017 4/30/2017 6/22/2017 7/24/2017 7/31/2017 10/30/2017 12/19/2017 8/28/2017 2/5/2018 6/11/2018 7/2/2018 7/2/2018 688930 810127 10000 120000 26000 85339 264000 20000 16000 68048 611463 200000 6500 9450 95000 26398 893491 473798 60000 495326 514476 112500 760758 163544 1950 90000 16.75 19.75 2.18 9.25 12.00 3.00 13.75 13.75 13.75 3.91 5.00 13.75 3.13 3.13 3.00 3.59 1.86 2.52 2.52 1.65 2.09 2.30 2.24 2.80 1.63 1.75 2/18/2020 7/27/2027 5/28/2020 10/28/2020 2/15/2021 1/13/2021 11/23/2021 5/18/2021 8/22/2021 12/1/2021 12/8/2021 2/22/2022 2/16/2022 3/8/2022 9/14/2022 4/30/2022 6/22/2022 7/24/2022 7/31/2022 10/30/2022 12/18/2022 2/28/2023 2/5/2023 6/11/2020 6/28/2023 1/2/2024

-3316384

187967

-7905519

-8618

-99667 10002 -114413 6695 -55622 169808 -169089 132884 -32954 11970 -48880 7960 -593960 250578 -709303 199970 -22859 7962 -33501 5279 195228 170131 88478 132712 -244170 23119 -278773 15818 1249287 5492 0 36 1249287 5492 0 36 -2007287 181244 -2346985 139325 -35800 1988 -43536 1695 -583516 28337 -676784 19661 -37970 2103 -50608 1914 -684859 34682 -799690 26587 -1132156 18478 -1748184 42609 -479399 22842 -974251 26389 33 -756261 0 -768188 1290000 2957400 0 1710000

13476000

6548000

20024000

9540000

2145000

2073000

2004000

1937000

1872000

453000

66000

238000

163000

69000

536000

95000

21000

26000

36000

40000

43000

11000

72000

53000

49000

34000

8294857

12879982

7742857

12567982

552000

312000

34805299

291234

434 408

30000

61501

3167196 2785932 1455844 1560641

88000

207000

EX-101.SCH 5 cvm-20190630.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - B. OPERATIONS AND FINANCING link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - C. STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - F. COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - G. PATENTS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - H. LOSS PER COMMON SHARE link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - I. SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - G. PATENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - H. LOSS PER COMMON SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - C. STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 5) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - G. PATENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - G. PATENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - H. LOSS PER COMMON SHARE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 cvm-20190630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 7 cvm-20190630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 8 cvm-20190630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class Of Warrant Or Right [Axis] Series W [Member] Series V [Member] Consultants [Member] Award Type [Axis] Incentive Stock Option Plans Non Qualified Stock Option Plans Stock Bonus Plans Stock Compensation Plan Series N [Member] Incentive Stock Bonus Plan Series X [Member] Series Y [Member] Series Z [Member] Series ZZ [Member] Series BB [Member] Series FF [Member] Series CC [Member] Series AA [Member] Series HH [Member] Series JJ [Member] Series II [Member] Series LL [Member] Series MM [Member] FairValueByFairValueHierarchyLevel [Axis] Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Series NN [Member] Series OO [Member] Series RR [Member] Series SS [Member] Series PP [Member] Geographical [Axis] Headquarters Research and Development Lab Antidilutive Securities [Axis] Options and Warrants Unvested Restricted Stock Series TT [Member] Series UU [Member] Series WW [Member] Series VV [Member] Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity's Reporting Status Current? Entity Filer Category Entity Emerging Growth Company Entity Small Business Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS CURRENT ASSETS: Cash and cash equivalents Receivables Prepaid expenses Inventory used for R&D and manufacturing Total current assets Plant, property and equipment, net Patent costs, net Deposits Total Assets LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable Accrued expenses Due to employees Derivative instruments, current portion Other current liabilities Total current liabilities Derivative instruments - net of current portion Lease Liability Deferred income Other liabilities Total liabilities COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding Common stock, $.01 par value - 600,000,000 shares authorized; 34,066,914 and 28,034,487 shares issued and outstanding at June 30, 2019 and September 30, 2018, respectively Additional paid-in capital Accumulated deficit Total stockholders' equity TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY Stockholders Equity Preferred Stock Shares Par Value Preferred Stock Shares Authorized Preferred Stock Shares Issued Preferred Stock Shares Outstanding Common Stock Shares Par Value Common Stock Shares Authorized Common Stock Shares Issued Common Stock Shares Outstanding Income Statement [Abstract] Grant income Operating Expenses: Research and development General & administrative Total operating expenses Operating loss Other income (Loss) gain on derivative instruments Other non-operating gain (loss) Interest expense, net Net loss available to common shareholders Net loss per common share Basic and Diluted Weighted average common shares outstanding Basic and Diluted Statement of Cash Flows [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Share-based payments for services Share-based payments for interest Equity based compensation Common stock contributed to 401(k) plan Shares issued for settlement of clinical research costs Loss on prepaid research and development Loss (gain) on derivative instruments Amortization of debt discount Inducement expense Capitalized lease interest (Increase)/decrease in assets: Receivables Prepaid expenses Inventory used for R&D and manufacturing Deposits Increase/(decrease) in liabilities: Accounts payable Accrued expenses Due to employees Other liabilities Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of equipment Expenditures for patent costs Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from issuance of common stock and warrants Payments of stock issuance costs Proceeds from exercise of warrants Proceeds from exercise of options Proceeds from the purchase of stock by officers and directors Payments on obligations under capital lease Net cash provided by financing activities NET DECREASE IN CASH AND CASH EQUIVALENTS CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD CASH AND CASH EQUIVALENTS, END OF PERIOD SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES: Capitalizable patent costs included in current liabilities Capital lease obligation included in accounts payable Exercise of derivative liabilities Stock issuance costs included in current liabilities Prepaid consulting services paid with issuance of common stock Notes payable converted into common shares Cash paid for interest expense Accounting Policies [Abstract] A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES B. Operations And Financing B. OPERATIONS AND FINANCING Equity [Abstract] C. STOCKHOLDERS' EQUITY Fair Value Disclosures [Abstract] D. FAIR VALUE MEASUREMENTS Related Party Transactions [Abstract] E. RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] F. COMMITMENTS AND CONTINGENCIES Intangible Assets, Net (Excluding Goodwill) [Abstract] G. PATENTS Earnings Per Share [Abstract] H. LOSS PER COMMON SHARE Subsequent Events [Abstract] I. SUBSEQUENT EVENTS Basis of Presentation Research and Office Equipment and Leasehold Improvements Patents Research and Development Costs Income Taxes Derivative Instruments Deferred Rent EX-101.PRE 9 cvm-20190630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 10 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Jun. 30, 2019	Aug. 13, 2019
Document And Entity Information
Entity Registrant Name	CEL SCI CORP
Entity Central Index Key	0000725363
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,805,299
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

XML 11 R2.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS - USD ($)	Jun. 30, 2019	Sep. 30, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 9,485,495	$ 10,310,044
Receivables	118,264	118,657
Prepaid expenses	233,784	364,622
Inventory used for R&D and manufacturing	754,825	645,238
Total current assets	10,592,368	11,438,561
Plant, property and equipment, net	15,948,864	16,218,851
Patent costs, net	272,488	258,093
Deposits	1,670,917	1,670,917
Total Assets	28,484,637	29,586,422
CURRENT LIABILITIES:
Accounts payable	2,078,800	5,743,913
Accrued expenses	122,030	205,310
Due to employees	761,027	764,941
Derivative instruments, current portion	1,249,835	2,498,606
Other current liabilities	16,009	14,029
Total current liabilities	4,227,701	9,226,799
Derivative instruments - net of current portion	9,482,995	6,818,458
Lease Liability	13,475,704	13,379,962
Deferred income	126,849	126,795
Other liabilities	25,084	33,492
Total liabilities	27,338,333	29,585,506
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Preferred stock, $.01 par value-200,000 shares authorized; -0- shares issued and outstanding	0	0
Common stock, $.01 par value - 600,000,000 shares authorized; 34,066,914 and 28,034,487 shares issued and outstanding at June 30, 2019 and September 30, 2018, respectively	340,669	280,346
Additional paid-in capital	349,683,796	331,312,184
Accumulated deficit	(348,878,161)	(331,591,614)
Total stockholders' equity	1,146,304	916
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 28,484,637	$ 29,586,422

XML 12 R3.htm IDEA: XBRL DOCUMENT

BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2019	Sep. 30, 2018
Stockholders Equity
Preferred Stock Shares Par Value	$ 0.01	$ 0.01
Preferred Stock Shares Authorized	200,000	200,000
Preferred Stock Shares Issued	0	0
Preferred Stock Shares Outstanding	0	0
Common Stock Shares Par Value	$ 0.01	$ 0.01
Common Stock Shares Authorized	600,000,000	600,000,000
Common Stock Shares Issued	34,066,914	28,034,487
Common Stock Shares Outstanding	34,066,914	28,034,487

XML 13 R4.htm IDEA: XBRL DOCUMENT

STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Grant income	$ 108,938	$ 86,459	$ 386,121	$ 297,045
Operating Expenses:
Research and development	2,298,555	2,425,562	7,956,203	7,713,873
General & administrative	3,020,482	1,748,971	6,981,079	5,823,694
Total operating expenses	5,319,037	4,174,533	14,937,282	13,537,567
Operating loss	(5,210,099)	(4,088,074)	(14,551,161)	(13,240,522)
Other income	18,448	17,711	54,575	52,984
(Loss) gain on derivative instruments	(7,905,519)	(8,618)	(3,316,384)	187,967
Other non-operating gain (loss)	1,455,844	(149,359)	1,877,197	(171,468)
Interest expense, net	(443,442)	(1,786,228)	(1,350,774)	(3,739,494)
Net loss available to common shareholders	$ (12,084,768)	$ (6,014,568)	$ (17,286,547)	$ (16,910,533)
Net loss per common share
Basic and Diluted	$ (0.37)	$ (0.36)	$ (0.58)	$ (1.17)
Weighted average common shares outstanding
Basic and Diluted	33,051,888	16,651,297	30,046,241	14,486,351

XML 14 R5.htm IDEA: XBRL DOCUMENT

STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
STATEMENTS OF CASH FLOWS - USD ($)	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (17,286,547)	$ (16,910,533)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	513,028	485,710
Share-based payments for services	688,070	349,319
Share-based payments for interest	0	80,716
Equity based compensation	2,626,311	2,193,402
Common stock contributed to 401(k) plan	108,485	109,073
Shares issued for settlement of clinical research costs	1,290,000	2,957,400
Loss on prepaid research and development	0	471,157
Loss (gain) on derivative instruments	3,316,384	(187,967)
Amortization of debt discount	0	1,956,424
Inducement expense	0	291,234
Capitalized lease interest	95,742	125,044
(Increase)/decrease in assets:
Receivables	393	98,829
Prepaid expenses	11,047	122,627
Inventory used for R&D and manufacturing	(109,587)	44,364
Deposits	0	150,000
Increase/(decrease) in liabilities:
Accounts payable	(3,567,182)	(1,960,438)
Accrued expenses	(113,280)	(74,856)
Due to employees	(3,914)	548,982
Other liabilities	(2,544)	4,819
Net cash used in operating activities	(12,433,594)	(9,144,694)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(171,321)	(1,015)
Expenditures for patent costs	(115,476)	(2,437)
Net cash used in investing activities	(286,797)	(3,452)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	0	7,091,536
Payments of stock issuance costs	(90,224)	(94,773)
Proceeds from exercise of warrants	11,657,590	2,133,677
Proceeds from exercise of options	97,290	0
Proceeds from the purchase of stock by officers and directors	234,997	0
Payments on obligations under capital lease	(3,811)	(5,082)
Net cash provided by financing activities	11,895,842	9,125,358
NET DECREASE IN CASH AND CASH EQUIVALENTS	(824,549)	(22,788)
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	10,310,044	2,369,438
CASH AND CASH EQUIVALENTS, END OF PERIOD	9,485,495	2,346,650
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Capitalizable patent costs included in current liabilities	30,000	61,501
Capital lease obligation included in accounts payable	434	408
Exercise of derivative liabilities	1,900,618	784,119
Stock issuance costs included in current liabilities	8,010	0
Prepaid consulting services paid with issuance of common stock	(119,791)	113,786
Notes payable converted into common shares	0	2,294,300
Cash paid for interest expense	$ 1,355,676	$ 1,312,664

XML 15 R6.htm IDEA: XBRL DOCUMENT

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

Summary of Significant Accounting Policies:

Research and Office Equipment and Leasehold Improvements – The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.

Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.

Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.

Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2019 and September 30, 2018.

Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.

Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense. For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.

Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's balance sheet.

Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as an expense over the requisite service or vesting period.

New Accounting Pronouncements

In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), (“ASU 2018-7”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, non-employee share-based payments would be measured at the grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure awards that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company’s financial position and results of operations.

In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (except of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. As permitted by the guidance, the Company has an option to retain the original lease classification and historical accounting for initial direct costs for leases existing prior to the adoption date. Furthermore, the Company will not have to reassess contracts entered into prior to the adoption date for the existence of a lease. The Company also has an option not to restate prior periods for the impact of the adoption of the new standard and may instead recognize a cumulative-effect adjustment to beginning retained earnings as of October 1, 2019 for any prior period income statement effects identified. The Company is evaluating the effect that adoption of this new standard will have on the Company’s financial statements and related disclosures.

The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

XML 16 R7.htm IDEA: XBRL DOCUMENT

B. OPERATIONS AND FINANCING

9 Months Ended

Jun. 30, 2019

B. Operations And Financing

B. OPERATIONS AND FINANCING

XML 17 R8.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY

9 Months Ended

Jun. 30, 2019

Equity [Abstract]

C. STOCKHOLDERS' EQUITY

The changes in stockholders’ equity during the nine months ended June 30, 2019 are as follows:

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2018		28,034,487		$	280,346		$	331,312,184		$	(331,591,614	)	$	916
Warrant exercises		298,682			2,987			646,766			-			649,753
401(k) contributions paid in common stock		12,279			123			35,118			-			35,241

Stock issued to nonemployees for services		62,784			628			201,752			-			202,380
Shares returned for settlement of clinical research costs		(564,905	)		(5,649	)		5,649			-			-
Equity based compensation - employees		-			-			573,660			-			573,660
Net income		-			-			-			1,245,902			1,245,902

BALANCES AT DECEMBER 31, 2018		27,843,327			278,435			332,775,129			(330,345,712	)		2,707,852

Warrant exercises		1,523,933			15,239			2,640,395			-			2,655,634
401(k) contributions paid in common stock		10,419			104			36,779			-			36,883
Stock issued to nonemployees for services		77,449			774			224,855			-			225,629
Equity based compensation - employees		(3,500	)		(35	)		530,865			-			530,830
Shares issued for settlement of clinical research costs		500,000			5,000			1,285,000			-			1,290,000
Stock issuance costs		-			-			(43,625	)		-			(43,625	)
Net loss		-			-			-			(6,447,681	)		(6,447,681	)

BALANCES AT MARCH 31, 2019		29,951,628			299,517			337,449,398			(336,793,393	)		955,522

Warrant exercises		4,014,109			40,141			10,212,680			-			10,252,821
401(k) contributions paid in common stock		4,339			43			36,318			-			36,361
Stock issued to nonemployees for services		20,825			208			140,062			-			140,270
Equity based compensation - employees		(4,000	)		(40	)		1,521,861			-			1,521,821
Option exercises		42,770			428			96,862			-			97,290
Purchase of stock by officers and directors		37,243			372			234,625			-			234,997
Stock issuance costs		-			-			(8,010	)		-			(8,010	)
Net loss		-			-			-			(12,084,768	)		(12,084,768	)
BALANCES AT JUNE 30, 2019		34,066,914		$	340,669		$	349,683,796		$	(348,878,161	)	$	1,146,304

The changes in stockholders’ deficit during the nine months ended June 30, 2018 are as follows:

					Additional
	Common		Stock		Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2017		11,903,133	$	119,031	$	296,298,401		$	(299,754,409	)	$	(3,336,977	)

Sale of common stock		1,289,478		12,895		2,437,105			-			2,450,000
401(k) contributions paid in common stock		18,984		190		35,690			-			35,880
Stock issued to nonemployees for services		13,705		137		25,270			-			25,407
Equity based compensation - employees		-		-		1,448,098			-			1,448,098
Warrants issued with notes payable		-		-		656,382			-			656,382
Conversion of notes payable to common stock		32,751		328		74,672			-			75,000
Net loss		-		-		-			(6,187,830	)		(6,187,830	)
BALANCES AT DECEMBER 31, 2017		13,258,051		132,581		300,975,618			(305,942,239	)		(4,834,040	)

Sale of common stock		2,501,145		25,011		4,652,130			-			4,677,141
401(k) contributions paid in common stock		25,901		259		36,261			-			36,520
Stock issued to nonemployees for services		124,082		1,241		227,254			-			228,495
Equity based compensation - employees		-		-		279,817			-			279,817
Conversion of notes payable to common stock		55,373		554		108,746			-			109,300
Shares issued for settlement of clinical research costs		660,000		6,600		1,240,800			-			1,247,400
Stock issuance cost		-		-		(94,773	)		-			(94,773	)
Net loss		-		-		-			(4,708,135	)		(4,708,135	)
BALANCES AT MARCH 31, 2018		16,624,552		166,246		307,425,853			(310,650,374	)		(3,058,275	)

Warrant exercises		1,117,644		11,177		2,906,619			-			2,917,796
401(k) contributions paid in common stock		39,862		399		36,274			-			36,673
Stock issued to nonemployees for services		81,604		816		208,387			-			209,203
Equity based compensation - employees		-		-		465,487			-			465,487
Conversion of notes payable and interest to common stock		1,106,806		11,068		2,179,648			-			2,190,716
Shares issued for settlement of clinical research costs		600,000		6,000		1,704,000			-			1,710,000
Warrants issued with notes payable		-		-		291,234			-			291,234
Net loss		-		-		-			(6,014,568	)		(6,014,568	)
BALANCES AT JUNE 30, 2018		19,570,468	$	195,706	$	315,217,502		$	(316,664,942	)	$	(1,251,734	)

Underlying share information for equity compensation plans as of June 30, 2019 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		138,400		99,962		N/A		385
Non-Qualified Stock Option Plans		6,387,200		6,193,237		N/A		115,156
Stock Bonus Plans		783,760		N/A		327,267		456,460
Stock Compensation Plan		634,000		N/A		122,221		493,369
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Underlying share information for equity compensation plans as of September 30, 2018 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		123,558		N/A		385
Non-Qualified Stock Option Plans		3,387,200		3,036,569		N/A		309,526
Stock Bonus Plans		783,760		N/A		297,230		486,497
Stock Compensation Plan		134,000		N/A		118,590		15,410
Incentive Stock Bonus Plan		640,000		N/A		624,000		16,000

Stock option activity:

	Nine Months Ended June 30,
	2019		2018
Granted		3,268,862		1,858,108
Exercised		42,770		-
Expired		29,322		26,395
Forfeited		63,698		1,393

	Three Months Ended June 30,
	2019		2018
Granted		3,268,362		1,847,808
Exercised		42,770		-
Expired		26,922		2,016
Forfeited		39,505		-

Warrants and Non-Employee Options

The following chart represents the warrants and non-employee options outstanding at June 30, 2019:

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	2/18/2020
Series V	5/28/2015		810,127	$	19.75	5/28/2020
Series UU	6/11/2018		163,544	$	2.80	6/11/2020
Series W	10/28/2015		688,930	$	16.75	10/28/2020
Series X	1/13/2016		120,000	$	9.25	1/13/2021
Series Y	2/15/2016		26,000	$	12.00	2/15/2021
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021
Series BB	8/26/2016		16,000	$	13.75	8/22/2021
Series Z	5/23/2016		264,000	$	13.75	11/23/2021
Series FF	12/8/2016		68,048	$	3.91	12/1/2021
Series CC	12/8/2016		611,463	$	5.00	12/8/2021
Series HH	2/23/2017		6,500	$	3.13	2/16/2022
Series AA	8/26/2016		200,000	$	13.75	2/22/2022
Series JJ	3/14/2017		9,450	$	3.13	3/8/2022
Series LL	4/30/2017		26,398	$	3.59	4/30/2022
Series MM	6/22/2017		893,491	$	1.86	6/22/2022
Series NN	7/24/2017		473,798	$	2.52	7/24/2022
Series OO	7/31/2017		60,000	$	2.52	7/31/2022
Series II	3/14/2017		95,000	$	3.00	9/14/2022
Series RR	10/30/2017		495,326	$	1.65	10/30/2022
Series SS	12/19/2017		514,476	$	2.09	12/18/2022
Series TT	2/5/2018		760,758	$	2.24	2/5/2023
Series PP	8/28/2017		112,500	$	2.30	2/28/2023
Series WW	7/2/2018		1,950	$	1.63	6/28/2023
Series VV	7/2/2018		90,000	$	1.75	1/2/2024
Consultants	7/28/17		10,000	$	2.18	7/27/2027

The table below presents the fair value of the warrant liabilities at the balance sheet dates:

	June 30, 2019		September 30, 2018
Series S warrants	$	-	$	33
Series V warrants		1,249,835		770,436
Series W warrants		2,131,237		999,081
Series Z warrants		1,172,626		487,767
Series ZZ warrants		72,185		34,215
Series AA warrants		963,990		380,474
Series BB warrants		64,256		28,456
Series CC warrants		3,699,989		1,779,724
Series DD warrants		-		1,249,287
Series EE warrants		-		1,249,287
Series FF warrants		433,091		188,921
Series GG warrants		-		607,228
Series HH warrants		44,050		58,816
Series II warrants		660,020		660,135
Series JJ warrants		64,252		88,642
Series KK warrants		-		656,930
Series LL warrants		177,299		77,632
Total warrant liabilities	$	10,732,830	$	9,317,064

The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:

	2019			2018
Series S warrants	$	33		$	(756,261	)
Series V warrants		(479,399	)		22,842
Series W warrants		(1,132,156	)		18,478
Series Z warrants		(684,859	)		34,682
Series ZZ warrants		(37,970	)		2,103
Series AA warrants		(583,516	)		28,337
Series BB warrants		(35,800	)		1,988
Series CC warrants		(2,007,287	)		181,244
Series DD warrants		1,249,287			5,492
Series EE warrants		1,249,287			5,492
Series FF warrants		(244,170	)		23,119
Series GG warrants		195,228			170,131
Series HH warrants		(22,859	)		7,962
Series II warrants		(593,960	)		250,578
Series JJ warrants		(32,954	)		11,970
Series KK warrants		(55,622	)		169,808
Series LL warrants		(99,667	)		10,002
Net (loss) gain on warrant liabilities	$	(3,316,384	)	$	187,967

The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:

	2019			2018
Series S warrants	$	-		$	(768,188	)
Series V warrants		(974,251	)		26,389
Series W warrants		(1,748,184	)		42,609
Series Z warrants		(799,690	)		26,587
Series ZZ warrants		(50,608	)		1,914
Series AA warrants		(676,784	)		19,661
Series BB warrants		(43,536	)		1,695
Series CC warrants		(2,346,985	)		139,325
Series DD warrants		-			36
Series EE warrants		-			36
Series FF warrants		(278,773	)		15,818
Series GG warrants		88,478			132,712
Series HH warrants		(33,501	)		5,279
Series II warrants		(709,303	)		199,970
Series JJ warrants		(48,880	)		7,960
Series KK warrants		(169,089	)		132,884
Series LL warrants		(114,413	)		6,695
Net loss on warrant liabilities	$	(7,905,519	)	$	(8,618	)

Expiration of Derivative Liabilities

2.	Securities Purchase Agreements

The following table summarizes the Other Non-Operating Gains (Loss) for the nine and three months ended June 30, 2019 and 2018 relating to these agreements:

	Nine Months Ended					Three Months Ended
	6/30/2019		6/30/2018			6/30/2019		6/30/2018
Amount realized through the sale of shares	$	3,167,197	$	2,785,932		$	1,455,844	$	1,560,641
Fair value of shares upon issuance		1,290,000		2,957,400			-		1,710,000
Other non-operating gain (loss)	$	1,877,197	$	(171,468	)	$	1,455,844	$	( 149,359	)

As of June 30, 2019, Ergomed holds 45,226 shares and may sell the shares or return the shares to the Company for cancellation until December 31, 2019.

3.	Incentive Stock Bonus Plan

During the nine and three months ended June 30, 2019, respectively, 7,500 and 4,000 shares of common stock issued from the 2014 Incentive Stock Bonus Plan were forfeited.

XML 18 R9.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS

9 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

D. FAIR VALUE MEASUREMENTS

In accordance with ASC 820-10, “Fair Value Measurements,” the Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The Company generally applies the income approach to determine fair value. This method uses valuation techniques to convert future amounts to a single present amount. The measurement is based on the value indicated by current market expectations with respect to those future amounts.

●	Level 1 – Observable inputs such as quoted prices in active markets for identical assets or liabilities

●

●	Level 3 – Unobservable inputs that reflect management’s assumptions

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2019:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

10,732,830

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2018:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

9,317,031

9,317,064

	Nine Months Ended			Year Ended
	June 30, 2019			September 30, 2018

Beginning balance	$	9,317,031		$	2,020,629
Issuances		—			—
Exercises		(1,900,618	)		(595,780	)
Realized and unrealized (gains) and losses		3,316,417			7,892,182
Ending balance	$	10,732,830		$	9,317,031

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 19 R10.htm IDEA: XBRL DOCUMENT

E. RELATED PARTY TRANSACTIONS	9 Months Ended
E. RELATED PARTY TRANSACTIONS	Jun. 30, 2019
Related Party Transactions [Abstract]
E. RELATED PARTY TRANSACTIONS	During the quarter ended June 30, 2019, the Company received security purchase agreements from five officers and directors of the Company for the purchase of 30,612 restricted shares of the Company’s common stock. The shares were sold at the aggregate fair market value on the closing date of approximately $210,000. Also during the current quarter, the Company’s CEO purchased 6,631 shares of restricted common stock for $25,000.

XML 20 R11.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES

9 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

F. COMMITMENTS AND CONTINGENCIES

Clinical Research Agreements

Lease Agreements

Approximate future minimum lease payments under the San Tomas lease as of June 30, 2019 are as follows:

Three months ending September 30, 2019	$	453,000
Year ending September 30,
2020		1,872,000
2021		1,937,000
2022		2,004,000
2023		2,073,000
2024		2,145,000
Thereafter		9,540,000
Total future minimum lease obligation		20,024,000
Less imputed interest on financing obligation		(6,548,000	)
Net present value of lease financing obligation	$	13,476,000

As of June 30, 2019, material contractual obligations, excluding the San Tomas lease, consisting of non-cancelable operating lease payments are as follows:

Three months ending September 30, 2019	$66,000
Year ending September 30,
2020	238,000
2021	163,000
2022	69,000
Total	$536,000

XML 21 R12.htm IDEA: XBRL DOCUMENT

G. PATENTS

9 Months Ended

Jun. 30, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

G. PATENTS

Three months ending September 30, 2019	$	11,000
Year ending September 30,
2020		43,000
2021		40,000
2022		36,000
2023		26,000
2024		21,000
Thereafter		95,000
Total	$	272,000

XML 22 R13.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE

9 Months Ended

Jun. 30, 2019

Net loss per common share

H. LOSS PER COMMON SHARE

In accordance with the contingently issuable shares guidance of FASB ASC Topic 260, Earnings Per Share, the calculation of diluted net earnings loss per share excludes the following securities because their inclusion would have been anti-dilutive as of June 30:

	2019		2018

Options and Warrants		7,742,857		12,567,982
Unvested Restricted Stock		552,000		312,000
Total		8,294,857		12,879,982

XML 23 R14.htm IDEA: XBRL DOCUMENT

I. SUBSEQUENT EVENTS

9 Months Ended

Jun. 30, 2019

Subsequent Events [Abstract]

I. SUBSEQUENT EVENTS

Between July 1, 2019 and August 13, 2019, the Company received approximately $2.6 million through the exercise of options and warrants to purchase shares of the Company’s common stock.

XML 24 R15.htm IDEA: XBRL DOCUMENT

A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES)	9 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	The accompanying condensed financial statements of CEL-SCI Corporation (the Company) are unaudited and certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission. While management of the Company believes that the disclosures presented are adequate to make the information presented not misleading, these interim condensed financial statements should be read in conjunction with the financial statements and notes included in the Company’s annual report on Form 10-K for the year ended September 30, 2018. In the opinion of management, the accompanying unaudited condensed financial statements contain all accruals and adjustments (each of which is of a normal recurring nature) necessary for a fair presentation of the Company’s financial position as of June 30, 2019 and the results of its operations for the nine and three months then ended. The condensed balance sheet as of September 30, 2018 is derived from the September 30, 2018 audited financial statements. Significant accounting policies have been consistently applied in the interim financial statements. The results of operations for the nine and three months ended June 30, 2019 are not necessarily indicative of the results to be expected for the entire year. The financial statements have been prepared assuming that the Company will continue as a going concern, but due to recurring losses from operations, which are expected for the foreseeable future, and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Refer to discussion in Note B.
Research and Office Equipment and Leasehold Improvements	Research and Office Equipment and Leasehold Improvements – The leased manufacturing facility is recorded at total project costs incurred and is depreciated over the 20-year useful life of the building. Research and office equipment is recorded at cost and depreciated using the straight-line method over estimated useful lives of five to seven years. Leasehold improvements are depreciated over the shorter of the estimated useful life of the asset or the term of the lease. Repairs and maintenance which do not extend the life of the asset are expensed when incurred. The fixed assets are reviewed on a quarterly basis to determine if any of the assets are impaired.
Patents	Patents - Patent expenditures are capitalized and amortized using the straight-line method over the shorter of the expected useful life or the legal life of the patent (17 years). In the event changes in technology or other circumstances impair the value or life of the patent, appropriate adjustment in the asset value and period of amortization is made. An impairment loss is recognized when estimated future undiscounted cash flows expected to result from the use of the asset, and from its disposition, are less than the carrying value of the asset. The amount of the impairment loss would be the difference between the estimated fair value of the asset and its carrying value.
Research and Development Costs	Research and Development Costs - Research and development costs are expensed as incurred. Management accrues Clinical Research Organization (“CRO”) expenses and clinical trial study expenses based on services performed and relies on the CROs to provide estimates of those costs applicable to the completion stage of a study. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. The Company charges revisions to estimated expense in the period in which the facts that give rise to the revision become known.
Income Taxes	Income Taxes - The Company uses the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating and tax loss carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be recognized. A full valuation allowance was recorded against the deferred tax assets as of June 30, 2019 and September 30, 2018. On December 22, 2017, the “Tax Cuts and Jobs Act” (the “Tax Act"), was signed into law by the President of the United States (U.S.). The Tax Act includes significant changes to corporate taxation, including reduction of the U.S. corporate tax rate from 35% to 21%, effective January 1, 2018, limitation of the tax deduction for interest expense to 30% of earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks. The Company has accounted for the income tax effects of the Act in applying FASB ASC 740 to the current reporting period. Because the Company records a valuation allowance for its entire deferred income tax asset, there was no impact to the amounts reported in the Company’s financial statements resulting from the Tax Act.
Derivative Instruments	Derivative Instruments – The Company has entered into financing arrangements that consist of freestanding derivative instruments that contain embedded derivative features. The Company accounts for these arrangements in accordance with Accounting Standards Codification (ASC) 815, “Accounting for Derivative Instruments and Hedging Activities.” In accordance with accounting principles generally accepted in the United States (U.S. GAAP), derivative instruments and hybrid instruments are recognized as either assets or liabilities in the balance sheet and are measured at fair value with gains or losses recognized in earnings or other comprehensive income depending on the nature of the derivative or hybrid instruments. The Company determines the fair value of derivative instruments and hybrid instruments based on available market data using appropriate valuation models considering all the rights and obligations of each instrument. The derivative liabilities are re-measured at fair value at the end of each interim period.
Deferred Rent	Deferred Rent– Certain of the Company’s operating leases provide for minimum annual payments that adjust over the life of the lease. The aggregate minimum annual payments are expensed on a straight-line basis over the minimum lease term. The Company recognizes a deferred rent liability for rent escalations when the amount of straight-line rent exceeds the lease payments, and reduces the deferred rent liability when the lease payments exceed the straight-line rent expense. For tenant improvement allowances and rent holidays, the Company records a deferred rent liability and amortizes the deferred rent over the lease term as a reduction to rent expense.
Leases	Leases – Leases are categorized as either operating or capital leases at inception. Operating lease costs are recognized on a straight-line basis over the term of the lease. An asset and a corresponding liability for the capital lease obligation are established for the cost of capital leases. The capital lease obligation is amortized over the life of the lease. For build-to-suit leases, the Company establishes an asset and liability for the estimated construction costs incurred to the extent that it is involved in the construction of structural improvements or takes construction risk prior to the commencement of the lease. Upon occupancy of facilities under build-to-suit leases, the Company assesses whether these arrangements qualify for sales recognition under the sale-leaseback accounting guidance. If a lease does not meet the criteria to qualify for a sale-leaseback transaction, the established asset and liability remain on the Company's balance sheet.
Stock-Based Compensation	Stock-Based Compensation – Compensation cost for all stock-based awards is measured at fair value as of the grant date in accordance with the provisions of ASC 718 “Compensation – Stock Compensation.” The fair value of stock options is calculated using the Black-Scholes option pricing model. The Black-Scholes model requires various judgmental assumptions including volatility and expected option life. The stock-based compensation cost is recognized on the straight-line allocation method as an expense over the requisite service or vesting period. Equity instruments issued to non-employees are accounted for in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Accordingly, compensation is recognized when goods or services are received and is measured using the Black-Scholes valuation model. The Black-Scholes model requires various judgmental assumptions regarding the fair value of the equity instruments at the measurement date and the expected life of the options. The Company has Incentive Stock Option Plans, Non-Qualified Stock Option Plans, a Stock Compensation Plan, Stock Bonus Plans and an Incentive Stock Bonus Plan. In some cases, these Plans are collectively referred to as the "Plans". All Plans have been approved by the stockholders. The Company’s stock options are not transferable, and the actual value of the stock options that an employee may realize, if any, will depend on the excess of the market price on the date of exercise over the exercise price. The Company has based its assumption for stock price volatility on the variance of daily closing prices of the Company’s stock. The risk-free interest rate assumption was based on the U.S. Treasury rate at date of the grant with term equal to the expected life of the option. Forfeitures are accounted for when they occur. The expected term of options represents the period that options granted are expected to be outstanding and has been determined based on an analysis of historical exercise behavior. If any of the assumptions used in the Black-Scholes model change significantly, stock-based compensation expense for new awards may differ materially in the future from that recorded in the current period. Vesting of restricted stock granted under the Incentive Stock Bonus Plan is subject to service, performance and market conditions and meets the classification of equity awards. These awards were measured at market value on the grant-dates for issuances where the attainment of performance criteria is likely and at fair value on the grant-dates, using a Monte Carlo simulation for issuances where the attainment of performance criteria is uncertain. The total compensation cost will be expensed over the estimated requisite service period.
New Accounting Pronouncements	In June 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-07, Compensation—Stock Compensation (Topic 718), (“ASU 2018-7”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of cost. Under current GAAP, non-employee share-based payment awards are measured at the fair value of the consideration received or the fair value of the equity instruments issued, whichever can be more reliably measured. Under ASU 2018-07, non-employee share-based payments would be measured at the grant-date fair value of the equity instruments an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Under current GAAP, the measurement date for equity classified non-employee share-based payment awards is the earlier of the date at which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. Under ASU 2018-07, equity-classified nonemployee share-based payment awards are measured at the grant date. The definition of the term grant date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. An entity should only remeasure liability-classified awards that have not been settled by the date of adoption and equity classified awards for which a measurement date has not been established through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Upon transition, the entity is required to measure these non-employee awards at fair value as of the adoption date. The entity must not remeasure awards that are completed. The Company is currently evaluating the impact the adoption of the standard will have on the Company’s financial position and results of operations. In February 2016, the FASB issued ASU 2016-02, Leases, which will require most leases (except of leases with terms of less than one year) to be recognized on the balance sheet as an asset and a lease liability. Leases will be classified as an operating lease or a financing lease. Operating leases are expensed using the straight-line method whereas financing leases will be treated similarly to a capital lease under the current standard. The new standard will be effective for annual and interim periods, within those fiscal years, beginning after December 15, 2018, but early adoption is permitted. The new standard must be presented using the modified retrospective method beginning with the earliest comparative period presented. As permitted by the guidance, the Company has an option to retain the original lease classification and historical accounting for initial direct costs for leases existing prior to the adoption date. Furthermore, the Company will not have to reassess contracts entered into prior to the adoption date for the existence of a lease. The Company also has an option not to restate prior periods for the impact of the adoption of the new standard and may instead recognize a cumulative-effect adjustment to beginning retained earnings as of October 1, 2019 for any prior period income statement effects identified. The Company is evaluating the effect that adoption of this new standard will have on the Company’s financial statements and related disclosures. The Company has considered all other recently issued accounting pronouncements and does not believe the adoption of such pronouncements will have a material impact on its financial statements.

XML 25 R16.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Tables)

9 Months Ended

Jun. 30, 2019

Equity [Abstract]

Changes in stockholders' equity

The changes in stockholders’ equity during the nine months ended June 30, 2019 are as follows:

							Additional
	Common			Stock			Paid-In			Accumulated
	Shares			Amount			Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2018		28,034,487		$	280,346		$	331,312,184		$	(331,591,614	)	$	916
Warrant exercises		298,682			2,987			646,766			-			649,753
401(k) contributions paid in common stock		12,279			123			35,118			-			35,241

Stock issued to nonemployees for services		62,784			628			201,752			-			202,380
Shares returned for settlement of clinical research costs		(564,905	)		(5,649	)		5,649			-			-
Equity based compensation - employees		-			-			573,660			-			573,660
Net income		-			-			-			1,245,902			1,245,902

BALANCES AT DECEMBER 31, 2018		27,843,327			278,435			332,775,129			(330,345,712	)		2,707,852

Warrant exercises		1,523,933			15,239			2,640,395			-			2,655,634
401(k) contributions paid in common stock		10,419			104			36,779			-			36,883
Stock issued to nonemployees for services		77,449			774			224,855			-			225,629
Equity based compensation - employees		(3,500	)		(35	)		530,865			-			530,830
Shares issued for settlement of clinical research costs		500,000			5,000			1,285,000			-			1,290,000
Stock issuance costs		-			-			(43,625	)		-			(43,625	)
Net loss		-			-			-			(6,447,681	)		(6,447,681	)

BALANCES AT MARCH 31, 2019		29,951,628			299,517			337,449,398			(336,793,393	)		955,522

Warrant exercises		4,014,109			40,141			10,212,680			-			10,252,821
401(k) contributions paid in common stock		4,339			43			36,318			-			36,361
Stock issued to nonemployees for services		20,825			208			140,062			-			140,270
Equity based compensation - employees		(4,000	)		(40	)		1,521,861			-			1,521,821
Option exercises		42,770			428			96,862			-			97,290
Purchase of stock by officers and directors		37,243			372			234,625			-			234,997
Stock issuance costs		-			-			(8,010	)		-			(8,010	)
Net loss		-			-			-			(12,084,768	)		(12,084,768	)
BALANCES AT JUNE 30, 2019		34,066,914		$	340,669		$	349,683,796		$	(348,878,161	)	$	1,146,304

The changes in stockholders’ deficit during the nine months ended June 30, 2018 are as follows:

					Additional
	Common		Stock		Paid-In			Accumulated
	Shares		Amount		Capital			Deficit			Total

BALANCES AT OCTOBER 1, 2017		11,903,133	$	119,031	$	296,298,401		$	(299,754,409	)	$	(3,336,977	)

Sale of common stock		1,289,478		12,895		2,437,105			-			2,450,000
401(k) contributions paid in common stock		18,984		190		35,690			-			35,880
Stock issued to nonemployees for services		13,705		137		25,270			-			25,407
Equity based compensation - employees		-		-		1,448,098			-			1,448,098
Warrants issued with notes payable		-		-		656,382			-			656,382
Conversion of notes payable to common stock		32,751		328		74,672			-			75,000
Net loss		-		-		-			(6,187,830	)		(6,187,830	)
BALANCES AT DECEMBER 31, 2017		13,258,051		132,581		300,975,618			(305,942,239	)		(4,834,040	)

Sale of common stock		2,501,145		25,011		4,652,130			-			4,677,141
401(k) contributions paid in common stock		25,901		259		36,261			-			36,520
Stock issued to nonemployees for services		124,082		1,241		227,254			-			228,495
Equity based compensation - employees		-		-		279,817			-			279,817
Conversion of notes payable to common stock		55,373		554		108,746			-			109,300
Shares issued for settlement of clinical research costs		660,000		6,600		1,240,800			-			1,247,400
Stock issuance cost		-		-		(94,773	)		-			(94,773	)
Net loss		-		-		-			(4,708,135	)		(4,708,135	)
BALANCES AT MARCH 31, 2018		16,624,552		166,246		307,425,853			(310,650,374	)		(3,058,275	)

Warrant exercises		1,117,644		11,177		2,906,619			-			2,917,796
401(k) contributions paid in common stock		39,862		399		36,274			-			36,673
Stock issued to nonemployees for services		81,604		816		208,387			-			209,203
Equity based compensation - employees		-		-		465,487			-			465,487
Conversion of notes payable and interest to common stock		1,106,806		11,068		2,179,648			-			2,190,716
Shares issued for settlement of clinical research costs		600,000		6,000		1,704,000			-			1,710,000
Warrants issued with notes payable		-		-		291,234			-			291,234
Net loss		-		-		-			(6,014,568	)		(6,014,568	)
BALANCES AT JUNE 30, 2018		19,570,468	$	195,706	$	315,217,502		$	(316,664,942	)	$	(1,251,734	)

Stock options, stock bonuses and compensation granted by the Company

Underlying share information for equity compensation plans as of June 30, 2019 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Options Plans		138,400		99,962		N/A		385
Non-Qualified Stock Option Plans		6,387,200		6,193,237		N/A		115,156
Stock Bonus Plans		783,760		N/A		327,267		456,460
Stock Compensation Plan		634,000		N/A		122,221		493,369
Incentive Stock Bonus Plan		640,000		N/A		616,500		23,500

Underlying share information for equity compensation plans as of September 30, 2018 is as follows:

Name of Plan	Total Shares Reserved Under Plans		Shares Reserved for Outstanding Options		Shares Issued		Remaining Options/Shares Under Plans

Incentive Stock Option Plans		138,400		123,558		N/A		385
Non-Qualified Stock Option Plans		3,387,200		3,036,569		N/A		309,526
Stock Bonus Plans		783,760		N/A		297,230		486,497
Stock Compensation Plan		134,000		N/A		118,590		15,410
Incentive Stock Bonus Plan		640,000		N/A		624,000		16,000

Stock option activity

	Nine Months Ended June 30,
	2019		2018
Granted		3,268,862		1,858,108
Exercised		42,770		-
Expired		29,322		26,395
Forfeited		63,698		1,393

	Three Months Ended June 30,
	2019		2018
Granted		3,268,362		1,847,808
Exercised		42,770		-
Expired		26,922		2,016
Forfeited		39,505		-

Derivative liabilities, warrants and other options

Warrant	Issue Date	Shares Issuable upon Exercise of Warrants		Exercise Price		Expiration Date
Series N	8/18/2008		85,339	$	3.00	2/18/2020
Series V	5/28/2015		810,127	$	19.75	5/28/2020
Series UU	6/11/2018		163,544	$	2.80	6/11/2020
Series W	10/28/2015		688,930	$	16.75	10/28/2020
Series X	1/13/2016		120,000	$	9.25	1/13/2021
Series Y	2/15/2016		26,000	$	12.00	2/15/2021
Series ZZ	5/23/2016		20,000	$	13.75	5/18/2021
Series BB	8/26/2016		16,000	$	13.75	8/22/2021
Series Z	5/23/2016		264,000	$	13.75	11/23/2021
Series FF	12/8/2016		68,048	$	3.91	12/1/2021
Series CC	12/8/2016		611,463	$	5.00	12/8/2021
Series HH	2/23/2017		6,500	$	3.13	2/16/2022
Series AA	8/26/2016		200,000	$	13.75	2/22/2022
Series JJ	3/14/2017		9,450	$	3.13	3/8/2022
Series LL	4/30/2017		26,398	$	3.59	4/30/2022
Series MM	6/22/2017		893,491	$	1.86	6/22/2022
Series NN	7/24/2017		473,798	$	2.52	7/24/2022
Series OO	7/31/2017		60,000	$	2.52	7/31/2022
Series II	3/14/2017		95,000	$	3.00	9/14/2022
Series RR	10/30/2017		495,326	$	1.65	10/30/2022
Series SS	12/19/2017		514,476	$	2.09	12/18/2022
Series TT	2/5/2018		760,758	$	2.24	2/5/2023
Series PP	8/28/2017		112,500	$	2.30	2/28/2023
Series WW	7/2/2018		1,950	$	1.63	6/28/2023
Series VV	7/2/2018		90,000	$	1.75	1/2/2024
Consultants	7/28/17		10,000	$	2.18	7/27/2027

Tabular disclosure of derivative liabilities at fair value

	June 30, 2019		September 30, 2018
Series S warrants	$	-	$	33
Series V warrants		1,249,835		770,436
Series W warrants		2,131,237		999,081
Series Z warrants		1,172,626		487,767
Series ZZ warrants		72,185		34,215
Series AA warrants		963,990		380,474
Series BB warrants		64,256		28,456
Series CC warrants		3,699,989		1,779,724
Series DD warrants		-		1,249,287
Series EE warrants		-		1,249,287
Series FF warrants		433,091		188,921
Series GG warrants		-		607,228
Series HH warrants		44,050		58,816
Series II warrants		660,020		660,135
Series JJ warrants		64,252		88,642
Series KK warrants		-		656,930
Series LL warrants		177,299		77,632
Total warrant liabilities	$	10,732,830	$	9,317,064

Schedule of gains and (losses) on derivative liabilities

The table below presents the gains/(losses) on the warrant liabilities for the nine months ended June 30:

	2019			2018
Series S warrants	$	33		$	(756,261	)
Series V warrants		(479,399	)		22,842
Series W warrants		(1,132,156	)		18,478
Series Z warrants		(684,859	)		34,682
Series ZZ warrants		(37,970	)		2,103
Series AA warrants		(583,516	)		28,337
Series BB warrants		(35,800	)		1,988
Series CC warrants		(2,007,287	)		181,244
Series DD warrants		1,249,287			5,492
Series EE warrants		1,249,287			5,492
Series FF warrants		(244,170	)		23,119
Series GG warrants		195,228			170,131
Series HH warrants		(22,859	)		7,962
Series II warrants		(593,960	)		250,578
Series JJ warrants		(32,954	)		11,970
Series KK warrants		(55,622	)		169,808
Series LL warrants		(99,667	)		10,002
Net (loss) gain on warrant liabilities	$	(3,316,384	)	$	187,967

The table below presents the gains/(losses) on the warrant liabilities for the three months ended June 30:

	2019			2018
Series S warrants	$	-		$	(768,188	)
Series V warrants		(974,251	)		26,389
Series W warrants		(1,748,184	)		42,609
Series Z warrants		(799,690	)		26,587
Series ZZ warrants		(50,608	)		1,914
Series AA warrants		(676,784	)		19,661
Series BB warrants		(43,536	)		1,695
Series CC warrants		(2,346,985	)		139,325
Series DD warrants		-			36
Series EE warrants		-			36
Series FF warrants		(278,773	)		15,818
Series GG warrants		88,478			132,712
Series HH warrants		(33,501	)		5,279
Series II warrants		(709,303	)		199,970
Series JJ warrants		(48,880	)		7,960
Series KK warrants		(169,089	)		132,884
Series LL warrants		(114,413	)		6,695
Net loss on warrant liabilities	$	(7,905,519	)	$	(8,618	)

Other non-operating gain (loss)

	Nine Months Ended					Three Months Ended
	6/30/2019		6/30/2018			6/30/2019		6/30/2018
Amount realized through the sale of shares	$	3,167,197	$	2,785,932		$	1,455,844	$	1,560,641
Fair value of shares upon issuance		1,290,000		2,957,400			-		1,710,000
Other non-operating gain (loss)	$	1,877,197	$	(171,468	)	$	1,455,844	$	( 149,359	)

XML 26 R17.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Jun. 30, 2019

Fair Value Disclosures [Abstract]

Measured at fair value on a recurring basis

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at June 30, 2019:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

10,732,830

The table below sets forth the assets and liabilities measured at fair value on a recurring basis, by input level, in the condensed balance sheet at September 30, 2018:

Quoted Prices in Active Markets for Identical Assets or Liabilities

(Level 1)

Significant Other Observable Inputs

(Level 2)

Significant Unobservable Inputs

(Level 3)

Total

Derivative instruments

9,317,031

9,317,064

Reconciliation of beginning and ending balances related to fair value measurements using significant unobservable inputs (Level 3)

	Nine Months Ended			Year Ended
	June 30, 2019			September 30, 2018

Beginning balance	$	9,317,031		$	2,020,629
Issuances		—			—
Exercises		(1,900,618	)		(595,780	)
Realized and unrealized (gains) and losses		3,316,417			7,892,182
Ending balance	$	10,732,830		$	9,317,031

XML 27 R18.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES (Tables)

9 Months Ended

Jun. 30, 2019

Commitments and Contingencies Disclosure [Abstract]

Future minimum lease payments under the San Tomas lease

Three months ending September 30, 2019	$	453,000
Year ending September 30,
2020		1,872,000
2021		1,937,000
2022		2,004,000
2023		2,073,000
2024		2,145,000
Thereafter		9,540,000
Total future minimum lease obligation		20,024,000
Less imputed interest on financing obligation		(6,548,000	)
Net present value of lease financing obligation	$	13,476,000

Schedule of future minimum payments under operating leases

Three months ending September 30, 2019	$66,000
Year ending September 30,
2020	238,000
2021	163,000
2022	69,000
Total	$536,000

XML 28 R19.htm IDEA: XBRL DOCUMENT

G. PATENTS (Tables)

9 Months Ended

Jun. 30, 2019

Intangible Assets, Net (Excluding Goodwill) [Abstract]

Schedule of total estimated future amortization

Three months ending September 30, 2019	$	11,000
Year ending September 30,
2020		43,000
2021		40,000
2022		36,000
2023		26,000
2024		21,000
Thereafter		95,000
Total	$	272,000

XML 29 R20.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE (Tables)

9 Months Ended

Jun. 30, 2019

Net loss per common share

Antidilutive securities

	2019		2018

Options and Warrants		7,742,857		12,567,982
Unvested Restricted Stock		552,000		312,000
Total		8,294,857		12,879,982

XML 30 R21.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details) - USD ($)	3 Months Ended						9 Months Ended
C. STOCKHOLDERS EQUITY (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2018	Dec. 31, 2017	Jun. 30, 2019	Jun. 30, 2018
Common Stock
Beginning balance	$ 299,517	$ 278,435	$ 280,346	$ 166,246	$ 132,581	$ 119,031	$ 280,346	$ 119,031
Beginning balance, shares	29,951,628	27,843,327	28,034,487	16,624,552	13,258,051	11,903,133	28,034,487	11,903,133
Sale of common stock					$ 25,011	$ 12,895
Sale of common stock, shares					2,501,145	1,289,478
Warrant exercises	$ 40,141	$ 15,239	$ 2,987	$ 11,177
Warrant exercises, shares	4,014,109	1,523,933	298,682	1,117,644
401(k) contributions paid in common stock	$ 43	$ 104	$ 123	$ 399	$ 259	$ 190
401(k) contributions paid in common stock, shares	4,339	10,419	12,279	39,862	25,901	18,984
Stock issued to nonemployees for service	$ 208	$ 774	$ 628	$ 816	$ 1,241	$ 137
Stock issued to nonemployees for service, shares	20,825	77,449	62,784	81,604	124,082	13,705
Conversion of notes payable and interest to common stock				$ 11,068	$ 554
Conversion of notes payable and interest to common stock, shares				1,106,806	55,373
Shares issued (returned) for settlement of clinical research costs		$ 5,000	$ (5,649)	$ 6,000	$ 6,600
Shares issued (returned) for settlement of clinical research costs, shares		500,000	(564,905)	600,000	660,000
Equity based compensation - employees	$ (40)	$ (35)
Equity based compensation - employees, shares	(4,000)	(3,500)
Option exercises	$ 428
Option exercises, shares	42,770
Purchase of stock by officers and directors	$ 372
Purchase of stock by officers and directors, shares	37,243
Ending balance	$ 340,669	$ 299,517	$ 278,435	$ 195,706	$ 166,246	$ 132,581	$ 340,669	$ 195,706
Ending balance, shares	34,066,914	29,951,628	27,843,327	19,570,468	16,624,552	13,258,051	34,066,914	19,570,468
Additional Paid-In Capital
Beginning balance	$ 337,449,398	$ 332,775,129	$ 331,312,184	$ 307,425,853	$ 300,975,618	$ 296,298,401	$ 331,312,184	$ 296,298,401
Sale of common stock					4,652,130	2,437,105
Warrant exercises	10,212,680	2,640,395	646,766	2,906,619
401(k) contributions paid in common stock	36,318	36,779	35,118	36,274	36,261	35,690
Stock issued to nonemployees for service	140,062	224,855	201,752	208,387	227,254	25,270
Conversion of notes payable and interest to common stock				2,179,648	108,746
Shares issued (returned) for settlement of clinical research costs		1,285,000	5,649	1,704,000	1,240,800
Equity based compensation - employees	1,521,861	530,865	573,660	465,487	279,817	1,448,098
Option exercises	96,862
Purchase of stock by officers and directors	234,625
Stock issuance cost	(8,010)	(43,625)			(94,773)
Warrants issued with notes payable				291,234
Ending balance	349,683,796	337,449,398	332,775,129	315,217,502	307,425,853	300,975,618	349,683,796	315,217,502
Accumulated Deficit
Beginning balance	(336,793,393)	(330,345,712)	(331,591,614)	(310,650,374)	(305,942,239)	(299,754,409)	(331,591,614)	(299,754,409)
Warrant exercises				0
Net income (loss)	(12,084,768)	(6,447,681)	1,245,902	(6,014,568)	(4,708,135)	(6,187,830)
Ending balance	(348,878,161)	(336,793,393)	(330,345,712)	(316,664,942)	(310,650,374)	(305,942,239)	(348,878,161)	(316,664,942)
Beginning balance	955,522	2,707,852	916	(3,058,275)	(4,834,040)	(3,336,977)	916	(3,336,977)
Sale of common stock					4,667,141	2,450,000
Warrant exercises	10,252,821	2,655,634	649,753	2,917,796
401(k) contributions paid in common stock	36,361	36,883	35,241	36,673	36,520	35,880	108,485	109,073
Stock issued to nonemployees for service	140,270	225,629	202,380	209,203	228,495	25,407
Conversion of notes payable and interest to common stock				2,190,716	109,300
Shares issued (returned) for settlement of clinical research costs		1,290,000	0	1,710,000	1,247,400
Equity based compensation - employees	1,521,821	530,830	573,660	465,487	279,817	1,448,098
Option exercises	97,290
Purchase of stock by officers and directors	234,997
Stock issuance cost	(8,010)	(43,625)			(94,773)
Warrants issued with notes payable				291,234
Net income (loss)	(12,084,768)	(6,447,681)	1,245,902	(6,014,568)	(4,708,135)	(6,187,830)	(17,286,547)	(16,910,533)
Ending balance	$ 1,146,304	$ 955,522	$ 2,707,852	$ (1,251,734)	$ (3,058,275)	$ (4,834,040)	$ 1,146,304	$ (1,251,734)

XML 31 R22.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 1) - shares	Jun. 30, 2019	Sep. 30, 2018
Incentive Stock Option Plans
Total shares reserved under plans	138,400	138,400
Shares reserved for outstanding options	99,962	123,558
Shares issued	0	0
Remaining options/shares under plans	385	385
Non Qualified Stock Option Plans
Total shares reserved under plans	6,387,200	3,387,200
Shares reserved for outstanding options	6,193,237	3,036,569
Shares issued	0	0
Remaining options/shares under plans	115,156	309,526
Stock Bonus Plans
Total shares reserved under plans	783,760	783,760
Shares reserved for outstanding options	0	0
Shares issued	327,267	297,230
Remaining options/shares under plans	456,460	486,497
Stock Compensation Plan
Total shares reserved under plans	634,000	134,000
Shares reserved for outstanding options	0	0
Shares issued	122,221	118,590
Remaining options/shares under plans	493,369	15,410
Incentive Stock Bonus Plan
Total shares reserved under plans	640,000	640,000
Shares reserved for outstanding options	0	0
Shares issued	616,500	624,000
Remaining options/shares under plans	23,500	16,000

XML 32 R23.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 2) - shares	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 2) - shares	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Granted	3,268,362	1,847,808	3,268,862	1,858,108
Exercised	42,770	0	42,770	0
Expired	26,922	2,016	29,322	26,395
Forfeited	39,505	0	63,698	1,393

XML 33 R24.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 3)	9 Months Ended
C. STOCKHOLDERS EQUITY (Details 3)	Jun. 30, 2019 $ / shares shares
Series N [Member]
STOCKHOLDERS' EQUITY
Issue date	8/18/2008
Shares issuable upon exercise of warrant \| shares	85,339
Exercise price \| $ / shares	$ 3.00
Expiration date	2/18/2020
Series V [Member]
STOCKHOLDERS' EQUITY
Issue date	5/28/2015
Shares issuable upon exercise of warrant \| shares	810,127
Exercise price \| $ / shares	$ 19.75
Expiration date	5/28/2020
Series UU [Member]
STOCKHOLDERS' EQUITY
Issue date	6/11/2018
Shares issuable upon exercise of warrant \| shares	163,544
Exercise price \| $ / shares	$ 2.80
Expiration date	6/11/2020
Series W [Member]
STOCKHOLDERS' EQUITY
Issue date	10/28/2015
Shares issuable upon exercise of warrant \| shares	688,930
Exercise price \| $ / shares	$ 16.75
Expiration date	10/28/2020
Series X [Member]
STOCKHOLDERS' EQUITY
Issue date	1/13/2016
Shares issuable upon exercise of warrant \| shares	120,000
Exercise price \| $ / shares	$ 9.25
Expiration date	1/13/2021
Series Y [Member]
STOCKHOLDERS' EQUITY
Issue date	2/15/2016
Shares issuable upon exercise of warrant \| shares	26,000
Exercise price \| $ / shares	$ 12.00
Expiration date	2/15/2021
Series ZZ [Member]
STOCKHOLDERS' EQUITY
Issue date	5/23/2016
Shares issuable upon exercise of warrant \| shares	20,000
Exercise price \| $ / shares	$ 13.75
Expiration date	5/18/2021
Series BB [Member]
STOCKHOLDERS' EQUITY
Issue date	8/26/2016
Shares issuable upon exercise of warrant \| shares	16,000
Exercise price \| $ / shares	$ 13.75
Expiration date	8/22/2021
Series Z [Member]
STOCKHOLDERS' EQUITY
Issue date	5/23/2016
Shares issuable upon exercise of warrant \| shares	264,000
Exercise price \| $ / shares	$ 13.75
Expiration date	11/23/2021
Series FF [Member]
STOCKHOLDERS' EQUITY
Issue date	12/8/2016
Shares issuable upon exercise of warrant \| shares	68,048
Exercise price \| $ / shares	$ 3.91
Expiration date	12/1/2021
Series CC [Member]
STOCKHOLDERS' EQUITY
Issue date	12/8/2016
Shares issuable upon exercise of warrant \| shares	611,463
Exercise price \| $ / shares	$ 5.00
Expiration date	12/8/2021
Series HH [Member]
STOCKHOLDERS' EQUITY
Issue date	2/23/2017
Shares issuable upon exercise of warrant \| shares	6,500
Exercise price \| $ / shares	$ 3.13
Expiration date	2/16/2022
Series AA [Member]
STOCKHOLDERS' EQUITY
Issue date	8/26/2016
Shares issuable upon exercise of warrant \| shares	200,000
Exercise price \| $ / shares	$ 13.75
Expiration date	2/22/2022
Series JJ [Member]
STOCKHOLDERS' EQUITY
Issue date	3/14/2017
Shares issuable upon exercise of warrant \| shares	9,450
Exercise price \| $ / shares	$ 3.13
Expiration date	3/8/2022
Series LL [Member]
STOCKHOLDERS' EQUITY
Issue date	4/30/2017
Shares issuable upon exercise of warrant \| shares	26,398
Exercise price \| $ / shares	$ 3.59
Expiration date	4/30/2022
Series MM [Member]
STOCKHOLDERS' EQUITY
Issue date	6/22/2017
Shares issuable upon exercise of warrant \| shares	893,491
Exercise price \| $ / shares	$ 1.86
Expiration date	6/22/2022
Series NN [Member]
STOCKHOLDERS' EQUITY
Issue date	7/24/2017
Shares issuable upon exercise of warrant \| shares	473,798
Exercise price \| $ / shares	$ 2.52
Expiration date	7/24/2022
Series OO [Member]
STOCKHOLDERS' EQUITY
Issue date	7/31/2017
Shares issuable upon exercise of warrant \| shares	60,000
Exercise price \| $ / shares	$ 2.52
Expiration date	7/31/2022
Series II [Member]
STOCKHOLDERS' EQUITY
Issue date	3/14/2017
Shares issuable upon exercise of warrant \| shares	95,000
Exercise price \| $ / shares	$ 3.00
Expiration date	9/14/2022
Series RR [Member]
STOCKHOLDERS' EQUITY
Issue date	10/30/2017
Shares issuable upon exercise of warrant \| shares	495,326
Exercise price \| $ / shares	$ 1.65
Expiration date	10/30/2022
Series SS [Member]
STOCKHOLDERS' EQUITY
Issue date	12/19/2017
Shares issuable upon exercise of warrant \| shares	514,476
Exercise price \| $ / shares	$ 2.09
Expiration date	12/18/2022
Series TT [Member]
STOCKHOLDERS' EQUITY
Issue date	2/5/2018
Shares issuable upon exercise of warrant \| shares	760,758
Exercise price \| $ / shares	$ 2.24
Expiration date	2/5/2023
Series PP [Member]
STOCKHOLDERS' EQUITY
Issue date	8/28/2017
Shares issuable upon exercise of warrant \| shares	112,500
Exercise price \| $ / shares	$ 2.30
Expiration date	2/28/2023
Series WW [Member]
STOCKHOLDERS' EQUITY
Issue date	7/2/2018
Shares issuable upon exercise of warrant \| shares	1,950
Exercise price \| $ / shares	$ 1.63
Expiration date	6/28/2023
Series VV [Member]
STOCKHOLDERS' EQUITY
Issue date	7/2/2018
Shares issuable upon exercise of warrant \| shares	90,000
Exercise price \| $ / shares	$ 1.75
Expiration date	1/2/2024
Consultants [Member]
STOCKHOLDERS' EQUITY
Issue date	7/28/2017
Shares issuable upon exercise of warrant \| shares	10,000
Exercise price \| $ / shares	$ 2.18
Expiration date	7/27/2027

XML 34 R25.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 4) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Sep. 30, 2018
Equity [Abstract]
Series S warrants	$ 0		$ 0		$ 33
Series V warrants	1,249,835		1,249,835		770,436
Series W warrants	2,131,237		2,131,237		999,081
Series Z warrants	1,172,626		1,172,626		487,767
Series ZZ warrants	72,185		72,185		34,215
Series AA warrants	963,990		963,990		380,474
Series BB warrants	64,256		64,256		28,456
Series CC warrants	3,699,989		3,699,989		1,779,724
Series DD warrants	0		0		1,249,287
Series EE warrants	0		0		1,249,287
Series FF warrants	433,091		433,091		188,921
Series GG warrants	0		0		607,228
Series HH warrants	44,050		44,050		58,816
Series II warrants	660,020		660,020		660,135
Series JJ warrants	64,252		64,252		88,642
Series KK warrants	0		0		656,930
Series LL warrants	177,299		177,299		77,632
Total warrant liabilities	10,732,830		10,732,830		$ 9,317,064
Series S warrants	0	$ (768,188)	33	$ (756,261)
Series V warrants	(974,251)	26,389	(479,399)	22,842
Series W warrants	(1,748,184)	42,609	(1,132,156)	18,478
Series Z warrants	(799,690)	26,587	(684,859)	34,682
Series ZZ warrants	(50,608)	1,914	(37,970)	2,103
Series AA warrants	(676,784)	19,661	(583,516)	28,337
Series BB warrants	(43,536)	1,695	(35,800)	1,988
Series CC warrants	(2,346,985)	139,325	(2,007,287)	181,244
Series DD warrants	0	36	1,249,287	5,492
Series EE warrants	0	36	1,249,287	5,492
Series FF warrants	(278,773)	15,818	(244,170)	23,119
Series GG warrants	88,478	132,712	195,228	170,131
Series HH warrants	(33,501)	5,279	(22,859)	7,962
Series II warrants	(709,303)	199,970	(593,960)	250,578
Series JJ warrants	(48,880)	7,960	(32,954)	11,970
Series KK warrants	(169,089)	132,884	(55,622)	169,808
Series LL warrants	(114,413)	6,695	(99,667)	10,002
Net (loss)/gain on warrant liabilities	$ (7,905,519)	$ (8,618)	$ (3,316,384)	$ 187,967

XML 35 R26.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details 5) - USD ($)	3 Months Ended		9 Months Ended
C. STOCKHOLDERS EQUITY (Details 5) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Equity [Abstract]
Amount realized through the sale of shares	$ 1,455,844	$ 1,560,641	$ 3,167,196	$ 2,785,932
Fair value of shares upon issuance	0	1,710,000	1,290,000	2,957,400
Other non-operating gain (loss)	$ 1,455,844	$ (149,359)	$ 1,877,197	$ (171,468)

XML 36 R27.htm IDEA: XBRL DOCUMENT

C. STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Non-employee stock based compensation expense	$ 88,000	$ 207,000

XML 37 R28.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Derivative instruments	$ 10,732,830	$ 9,317,064
Quoted Prices in Active Markets for Identical Assets or Liabilities (Level 1)
Derivative instruments	0	33
Significant Other Observable Inputs (Level 2)
Derivative instruments	0	0
Significant Unobservable Inputs (Level 3)
Derivative instruments	$ 10,732,830	$ 9,317,031

XML 38 R29.htm IDEA: XBRL DOCUMENT

D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	9 Months Ended	12 Months Ended
D. FAIR VALUE MEASUREMENTS (Details 1) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Fair Value Disclosures [Abstract]
Beginning balance	$ 9,317,031	$ 2,020,629
Issuances	0	0
Exercises	(1,900,618)	(595,780)
Realized and unrealized (gains) and losses	3,316,417	7,892,182
Ending balance	$ 10,732,830	$ 9,317,031

XML 39 R30.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES (Details)	Jun. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Three months ending September 30, 2019	$ 453,000
2020	1,872,000
2021	1,937,000
2022	2,004,000
2023	2,073,000
2024	2,145,000
Thereafter	9,540,000
Total future minimum lease obligation	20,024,000
Less imputed interest on financing obligation	(6,548,000)
Net present value of lease financing obligation	$ 13,476,000

XML 40 R31.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES (Details 1)	Jun. 30, 2019 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Three months ending September 30, 2019	$ 66,000
2020	238,000
2021	163,000
2022	69,000
Total	$ 536,000

XML 41 R32.htm IDEA: XBRL DOCUMENT

F. COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Research and Development Lab
Deferred rent liability	$ 14,000	$ 12,000
Headquarters
Deferred rent liability	$ 9,000	$ 14,000

XML 42 R33.htm IDEA: XBRL DOCUMENT

G. PATENTS (Details) - USD ($)	Jun. 30, 2019	Sep. 30, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Three months ending September 30, 2019	$ 11,000
2020	43,000
2021	40,000
2022	36,000
2023	26,000
2024	21,000
Thereafter	95,000
Total	$ 272,488	$ 258,093

XML 43 R34.htm IDEA: XBRL DOCUMENT

G. PATENTS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
G. PATENTS (Details Narrative) - USD ($)	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Amortization of patent costs	$ 49,000	$ 34,000	$ 72,000	$ 53,000

XML 44 R35.htm IDEA: XBRL DOCUMENT

H. LOSS PER COMMON SHARE (Details) - shares	9 Months Ended
H. LOSS PER COMMON SHARE (Details) - shares	Jun. 30, 2019	Jun. 30, 2018
Antidilutive securities	8,294,857	12,879,982
Options and Warrants
Antidilutive securities	7,742,857	12,567,982
Unvested Restricted Stock
Antidilutive securities	552,000	312,000

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 136 298 1 false 41 0 false 3 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://cel-sci.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - BALANCE SHEETS Sheet http://cel-sci.com/role/BalanceSheets BALANCE SHEETS Statements 2 false false R3.htm 00000003 - Statement - BALANCE SHEETS (Parenthetical) Sheet http://cel-sci.com/role/BalanceSheetsParenthetical BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - STATEMENTS OF OPERATIONS Sheet http://cel-sci.com/role/StatementsOfOperations STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - STATEMENTS OF CASH FLOWS Sheet http://cel-sci.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 00000006 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPolicies A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 6 false false R7.htm 00000007 - Disclosure - B. OPERATIONS AND FINANCING Sheet http://cel-sci.com/role/B.OperationsAndFinancing B. OPERATIONS AND FINANCING Notes 7 false false R8.htm 00000008 - Disclosure - C. STOCKHOLDERS EQUITY Sheet http://cel-sci.com/role/C.StockholdersEquity C. STOCKHOLDERS EQUITY Notes 8 false false R9.htm 00000009 - Disclosure - D. FAIR VALUE MEASUREMENTS Sheet http://cel-sci.com/role/D.FairValueMeasurements D. FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 00000010 - Disclosure - E. RELATED PARTY TRANSACTIONS Sheet http://cel-sci.com/role/E.RelatedPartyTransactions E. RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 00000011 - Disclosure - F. COMMITMENTS AND CONTINGENCIES Sheet http://cel-sci.com/role/F.CommitmentsAndContingencies F. COMMITMENTS AND CONTINGENCIES Notes 11 false false R12.htm 00000012 - Disclosure - G. PATENTS Sheet http://cel-sci.com/role/G.Patents G. PATENTS Notes 12 false false R13.htm 00000013 - Disclosure - H. LOSS PER COMMON SHARE Sheet http://cel-sci.com/role/H.LossPerCommonShare H. LOSS PER COMMON SHARE Notes 13 false false R14.htm 00000014 - Disclosure - I. SUBSEQUENT EVENTS Sheet http://cel-sci.com/role/I.SubsequentEvents I. SUBSEQUENT EVENTS Notes 14 false false R15.htm 00000015 - Disclosure - A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Sheet http://cel-sci.com/role/A.BasisOfPresentationAndSummaryOfSignificantAccountingPoliciesPolicies A. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (POLICIES) Notes 15 false false R16.htm 00000016 - Disclosure - C. STOCKHOLDERS EQUITY (Tables) Sheet http://cel-sci.com/role/C.StockholdersEquityTables C. STOCKHOLDERS EQUITY (Tables) Tables http://cel-sci.com/role/C.StockholdersEquity 16 false false R17.htm 00000017 - Disclosure - D. FAIR VALUE MEASUREMENTS (Tables) Sheet http://cel-sci.com/role/D.FairValueMeasurementsTables D. FAIR VALUE MEASUREMENTS (Tables) Tables http://cel-sci.com/role/D.FairValueMeasurements 17 false false R18.htm 00000018 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://cel-sci.com/role/F.CommitmentsAndContingenciesTables F. COMMITMENTS AND CONTINGENCIES (Tables) Tables http://cel-sci.com/role/F.CommitmentsAndContingencies 18 false false R19.htm 00000019 - Disclosure - G. PATENTS (Tables) Sheet http://cel-sci.com/role/G.PatentsTables G. PATENTS (Tables) Tables http://cel-sci.com/role/G.Patents 19 false false R20.htm 00000020 - Disclosure - H. LOSS PER COMMON SHARE (Tables) Sheet http://cel-sci.com/role/H.LossPerCommonShareTables H. LOSS PER COMMON SHARE (Tables) Tables http://cel-sci.com/role/H.LossPerCommonShare 20 false false R21.htm 00000021 - Disclosure - C. STOCKHOLDERS EQUITY (Details) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails C. STOCKHOLDERS EQUITY (Details) Details http://cel-sci.com/role/C.StockholdersEquityTables 21 false false R22.htm 00000022 - Disclosure - C. STOCKHOLDERS EQUITY (Details 1) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails1 C. STOCKHOLDERS EQUITY (Details 1) Details http://cel-sci.com/role/C.StockholdersEquityTables 22 false false R23.htm 00000023 - Disclosure - C. STOCKHOLDERS EQUITY (Details 2) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails2 C. STOCKHOLDERS EQUITY (Details 2) Details http://cel-sci.com/role/C.StockholdersEquityTables 23 false false R24.htm 00000024 - Disclosure - C. STOCKHOLDERS EQUITY (Details 3) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails3 C. STOCKHOLDERS EQUITY (Details 3) Details http://cel-sci.com/role/C.StockholdersEquityTables 24 false false R25.htm 00000025 - Disclosure - C. STOCKHOLDERS EQUITY (Details 4) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails4 C. STOCKHOLDERS EQUITY (Details 4) Details http://cel-sci.com/role/C.StockholdersEquityTables 25 false false R26.htm 00000026 - Disclosure - C. STOCKHOLDERS EQUITY (Details 5) Sheet http://cel-sci.com/role/C.StockholdersEquityDetails5 C. STOCKHOLDERS EQUITY (Details 5) Details http://cel-sci.com/role/C.StockholdersEquityTables 26 false false R27.htm 00000027 - Disclosure - C. STOCKHOLDERS EQUITY (Details Narrative) Sheet http://cel-sci.com/role/C.StockholdersEquityDetailsNarrative C. STOCKHOLDERS EQUITY (Details Narrative) Details http://cel-sci.com/role/C.StockholdersEquityTables 27 false false R28.htm 00000028 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails D. FAIR VALUE MEASUREMENTS (Details) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 28 false false R29.htm 00000029 - Disclosure - D. FAIR VALUE MEASUREMENTS (Details 1) Sheet http://cel-sci.com/role/D.FairValueMeasurementsDetails1 D. FAIR VALUE MEASUREMENTS (Details 1) Details http://cel-sci.com/role/D.FairValueMeasurementsTables 29 false false R30.htm 00000030 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details) Sheet http://cel-sci.com/role/F.CommitmentsAndContingenciesDetails F. COMMITMENTS AND CONTINGENCIES (Details) Details http://cel-sci.com/role/F.CommitmentsAndContingenciesTables 30 false false R31.htm 00000031 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details 1) Sheet http://cel-sci.com/role/F.CommitmentsAndContingenciesDetails1 F. COMMITMENTS AND CONTINGENCIES (Details 1) Details http://cel-sci.com/role/F.CommitmentsAndContingenciesTables 31 false false R32.htm 00000032 - Disclosure - F. COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://cel-sci.com/role/F.CommitmentsAndContingenciesDetailsNarrative F. COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://cel-sci.com/role/F.CommitmentsAndContingenciesTables 32 false false R33.htm 00000033 - Disclosure - G. PATENTS (Details) Sheet http://cel-sci.com/role/G.PatentsDetails G. PATENTS (Details) Details http://cel-sci.com/role/G.PatentsTables 33 false false R34.htm 00000034 - Disclosure - G. PATENTS (Details Narrative) Sheet http://cel-sci.com/role/G.PatentsDetailsNarrative G. PATENTS (Details Narrative) Details http://cel-sci.com/role/G.PatentsTables 34 false false R35.htm 00000035 - Disclosure - H. LOSS PER COMMON SHARE (Details) Sheet http://cel-sci.com/role/H.LossPerCommonShareDetails H. LOSS PER COMMON SHARE (Details) Details http://cel-sci.com/role/H.LossPerCommonShareTables 35 false false All Reports Book All Reports cvm-20190630.xml cvm-20190630.xsd cvm-20190630_cal.xml cvm-20190630_def.xml cvm-20190630_lab.xml cvm-20190630_pre.xml http://fasb.org/us-gaap/2019-01-31 http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2018-01-31 true true ZIP 50 0001654954-19-009579-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001654954-19-009579-xbrl.zip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end